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Abstract
Tuberculosis kills more people worldwide than any other single infectious
disease agent, a threat made more dire by the spread of drug-resistant strains
of  . Development of new vaccines capable ofMycobacterium tuberculosis (Mtb)
preventing TB disease and new   infection are an essential component ofMtb
the strategy to combat the TB epidemic. Accordingly, the WHO considers the
development of new TB vaccines a major public health priority. In October
2017, the WHO convened a consultation with global leaders in the TB vaccine
development field to emphasize the WHO commitment to this effort and to
facilitate creative approaches to the discovery and development of TB vaccine
candidates. This review summarizes the presentations at this consultation,
updated with scientific literature references, and includes discussions of the
public health need for a TB vaccine; the status of efforts to develop vaccines to
replace or potentiate BCG in infants and develop new TB vaccines for
adolescents and adults; strategies being employed to diversify vaccine
platforms; and new animal models being developed to facilitate TB vaccine
development. A perspective on the status of these efforts from the major
funders and organizational contributors also is included. This presentation
highlights the extraordinary progress being made to develop new TB vaccines
and provided a clear picture of the exciting development pathways that are
being explored.
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1. Public health need for new tuberculosis vaccines 
and landscape analysis
a. Introduction
The World Health Organization (WHO) provides guidance on 
priority targets and development pathways for vaccines against 
diseases of high public health interest. The involvement of the 
WHO in vaccine development is driven by assessments of medi-
cal need and technical feasibility, and an absence of market 
incentives and sufficient funding to adequately drive the devel-
opment process. As tuberculosis (TB) kills more people globally 
than any other single infectious agent1, developing a TB vaccine 
ranks among the highest global health priorities from a medi-
cal needs perspective. A number of factors support the technical 
feasibility of a TB vaccine, including the fact that an estimated 
90% of persons infected with Mycobacterium tuberculosis 
(Mtb) do not progress to active disease1, evidence suggesting 
that past Mtb infection provides some protection against new 
infections2,3, and the existence of a century-old vaccine, Bacil-
lus Calmette-Guérin (BCG), that provides partial protection in 
children which may, under some circumstances, extend for 
decades4. The current imperative is to improve our understand-
ing of the type of immunological responses needed to provide 
robust protection against Mtb infection or TB disease, and to use 
this information to efficiently develop new, safe and effective 
TB vaccines.
In response to the compelling public health need for a TB 
vaccine, in October 2017 the WHO convened experts and 
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representatives of important stakeholder institutions involved 
in vaccine development to assist the WHO in a two-pronged 
effort to accelerate TB vaccine development. The first effort 
was dedicated to defining a preferred product characteristics 
(PPC) guidance document for new TB vaccines, now publicly 
available5. The second was to convene a meeting providing 
an opportunity for the exchange of cutting-edge information 
relevant to TB vaccine development, from basic science to later 
stage research. The proceedings of this meeting are summarized 
in this document.
b. The WHO Global TB Programme
Each year, the WHO publishes the Global Tuberculosis Report, 
documenting the overall status of the global TB epidemic. The 
2017 version of this report highlights the following statistics for 
the state of the TB epidemic in 20161:
•    1,674,000 TB deaths, of which 374,000 were in HIV 
co-infected persons (“the ninth leading cause of death 
worldwide and the leading cause from a single infectious 
agent, ranking above HIV/AIDS”1); 374,000 of these 
deaths occurring in HIV-infected persons
•    10.4 million cases of TB disease, 56% of which were in 
5 countries: India, Indonesia, China, the Philippines and 
Pakistan;
•    600,000 cases of rifampicin-resistant TB (RR-TB), of 
which 490,000 were multidrug-resistant TB (MDR-TB). 
Globally, an estimated 4.1% of new cases and 19% of 
previously treated cases had MDR or RR-TB, with 47% 
of the global total of drug-resistant cases reported from 
China, India and the Russian Federation. 250,000 of these 
490,000 died.
•    A U.S. $2.3 billion funding gap for financing TB care 
and prevention existed in 2017
The WHO strategy to tackle the global epidemic of TB was 
set forth in the WHO End TB Strategy, endorsed by the WHO 
General Assembly in 20146. The End TB Strategy relies on a 
number of priorities in the global response to the TB epidemic. 
These priorities include improving approaches to identifying 
cases of TB, addressing MDR-TB as a true public health 
crisis, and accelerating strategies to better prevent, identify and 
treat TB in HIV-infected individuals. A three-pillared approach 
to the TB epidemic is being implemented: 1) to advocate for inte-
grated, patient-centered TB care and prevention; 2) to support 
the creation of bold policies and supportive systems to curb 
the spread of TB; and 3) to support intensive research and 
innovation to create the new tools needed to prevent and treat 
control TB, including better diagnostics and drugs, and a new 
vaccine capable of preventing TB disease.
A key objective of the WHO End TB Strategy is a 90% reduc-
tion in TB incidence, from the 2015 annual incidence of greater 
than 100 cases per 100,000 population to less than 10 cases per 
100,000 persons by 20356. Currently, the annual decline in TB 
incidence is not nearly fast enough to meet the expressed goals1. 
As evidenced by the successes of the social protections provided 
under the Marshall Plan in the aftermath of World War II, 
a 10% rate of decline could be considered feasible through 
optimization of currently available social and medical interven-
tions. Though this is a major proposition in and of itself, which 
would require a heightened degree of global commitment to 
this effort. Without the development of new TB prevention 
modalities, however, this rate would be expected to flatten out 
to a 5% decline per year by 2025, again, not nearly sufficient 
to meet the End TB Strategy 2035 goals6. Only the introduction 
of new tools, including better point-of-care diagnostics capa-
ble of quickly and reliably diagnosing TB, including cases of 
drug-resistant (DR) TB; better drugs for treating drug-sensitive 
and DR-TB over a shorter period of time than is currently 
required; and, most importantly, a new vaccine capable of 
preventing TB disease, introduced by 2025, would result in 
an acceleration to the 17% per year decline of TB incidence 
necessary to meet the 2035 goals6.
Currently, a 2.3 billion U.S dollar (USD) annual research gap 
exists in efforts to develop new tools to control TB, including 
better diagnostics and drugs, as well as TB vaccines1. Given the 
ambitious targets set by the WHO End TB Strategy, the $2.3 
billion gap represents a conservative estimate, particularly 
considering the absolute need to develop an effective vaccine by 
2025 for the targets to be reached. The ongoing United Nations 
(UN)–led efforts to prioritize action against TB is illustrated 
by a series of high-level political meetings. Top-level political 
engagement was demonstrated in Russia in November 2017 
at the gathering of 194 ministers of health, research and finance, 
alongside the WHO Director General and the President of 
the UN General Assembly. This was followed by an interactive 
civil society meeting, attended by more than 250 representatives 
from civil society, academia, NGOs, and the private sector, 
setting the stage for the first ever UN General Assembly high 
level meeting (HLM) on TB in New York in September 2018. 
The HLM aims to deliver an ambitious political declaration 
on TB endorsed by Heads of State, which will strengthen action 
and investments to end TB. Issues to be discussed include the 
increase in drug-resistant TB strains, the need to provide ade-
quate resources to control the epidemic, and to create a universal 
monitoring program to track the epidemic and the world’s 
response to it, will be highlighted. Accelerating development 
of a vaccine for TB will be a critical component in the future of 
TB prevention and care, therefore urgently requires increased 
resource allocation and political support in upcoming years.
c. The value proposition for TB vaccines
A key question that arises when attempting to assess the value 
of TB vaccines is how to measure “value”. Possible measures of 
value include the payer perspective – savings in direct health-
care costs resulting from the protective effect of vaccines; a 
human perspective – assessing reductions in death and disability; 
and a societal perspective – determining the overall benefits to 
society that result from vaccine-induced protection. Different 
stakeholders will have different views on which of these 
approaches best defines the value of vaccines. Perspectives of vac-
cine value also will differ based on whether the value proposition 
involves a regional, countrywide, or global assessment.
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A model of the health impact of the introduction in 2024 in low 
and middle income countries of a 60% efficacious vaccine with 10 
years protection delivered to adolescents and adults, with cover-
age equal to school attendance for routine vaccination of 10 year 
olds and 72–76% for periodic mass campaigns, suggests that 
approximately 17 million TB cases could be averted between 
2024 and 20507. If such vaccine were to be administered to 
infants, with approximately 90% coverage rate, 890,000 TB cases 
would be cumulatively averted by 2050. These benefits need to 
be weighed against the total systems cost of vaccine administra-
tion, including the purchase price and the cost of administration, 
transportation and storage, national program management and 
the facilities and equipment necessary to deliver and admin-
ister a vaccine. In the modelled scenarios above, the median 
cost per disability-adjusted life year (DALY) averted in low or 
middle income settings ranged from cost saving to $720 per 
DALY averted in the adult/adolescent scenario, and $1,690–
$18,110 per DALY averted in the infant scenario7. Issues faced in 
the early stages of vaccine development, such as efficacy and 
duration of protection, and issues arising later, such as vaccine 
price, regimen of administration, thermostability and avail-
ability (overall supply) all contribute to the cost of vaccine 
administration and should be taken into consideration at the very 
earliest stages of the development of a vaccine.
d. Overview of the TB vaccine clinical pipeline
Currently, multiple vaccine candidates are being assessed in 
clinical trials. Vaccine strategies being assessed include live, 
attenuated mycobacteria (MTBVAC, VPM-1002); killed, whole 
cell mycobacteria (DAR-901, M. vaccae, MIP), mycobacte-
rial extracts (RUTI); adjuvanted protein vaccines (M72/AS01E, 
H4:IC31 (discontinued), H56:IC31, ID93 + GLA-SE), and 
viral vectored vaccines (Ad5Ag85A, ChAdOx185A/MVA85A, 
TB/FLU-04L). Although the target populations in these trials 
include adolescents, adults and infants, it is generally recognized 
that vaccinating adolescents and adults represents the most 
efficient means of stopping the cycle of Mtb transmission and 
thereby offers the best opportunity to control the global spread 
of Mtb, even to infants and children7,8.
Four potential indications have been identified as targets for TB 
vaccine development in adolescents and adults: 1) prevention of 
TB disease (PoD); 2) prevention of recurrent TB disease, which 
can be related to relapse or re-infection, in persons cured post-
treatment for active disease (PoR); 3) prevention of established 
Mtb infection in persons uninfected with Mtb (PoI); and 4) as an 
immunotherapeutic adjunct to drug treatment to shorten curative 
regimens or increase the efficacy of treatment of drug-resistant 
strains. In infants, the major goals have been to develop a vac-
cine that is more efficacious and/or safer than BCG that could 
serve as a BCG replacement and to develop a booster to improve 
and extend the protection provided by BCG.
PoD represents the highest priority indication, as modeling 
suggests that preventing TB disease in adolescents and adults 
would be the quickest way to control the global TB epidemic7,8. 
The major issue in developing a vaccine for a PoD indica-
tion, however, is the cost of conducting late-stage efficacy trials 
given the relatively large sample sizes and prolonged period of 
post-vaccination follow-up required to accrue adequate endpoints 
in the general, healthy population. In light of this, novel trial 
designs for phase 2 proof of concept studies have been devel-
oped to reduce the risk of failure in expensive late-stage 
trials. These novel designs have focused on assessing candi-
date TB vaccines for clinically meaningful biological effects in 
selected high-risk populations, to allow shorter, less expensive 
trials for assessment of efficacy.
One such novel design is based on prevention of recurrent TB 
disease in recently cured TB patients since this population is 
at an elevated risk of developing TB compared to individuals 
that have never had TB, due either to reinfection or to reactiva-
tion of existing infection. While a PoR endpoint could serve as 
a licensable indication in its own right, it currently is also being 
assessed as a possible means of de-risking a decision to move a 
vaccine candidate forward into late-stage PoD evaluations in 
the general population9,10.
Assessing the ability of a candidate vaccine to prevent estab-
lishment of de novo Mtb infection represents another strategy to 
demonstrate a clinically meaningful biological effect. If popula-
tions experiencing a high force of Mtb infection were recruited, 
such as adolescents in the Western Cape of South Africa, a PoI 
endpoint trial could potentially be less expensive to conduct than 
a PoR trial11. Results from a PoI trial of the adjuvanted protein 
vaccine, H4:IC31 versus BCG revaccination, conducted in 
adolescents in the Western Cape were recently published (after 
the meeting reported here). This trial demonstrated that neither 
the H4:IC31 vaccine nor revaccination with the BCG vaccine 
prevented initial quantiferon (QFT) conversion (efficacy 
point estimates of 9.4%, P=0.63 for H4:IC31; 20.1%, P=0.29 
for BCG). BCG revaccination, however, reduced the rate of 
sustained QFT conversion (efficacy 45.4%, P=0.03); efficacy of 
sustained QFT conversion for H4:IC31 was 30.5%, P=0.16)12. The 
implications of these results for BCG revaccination strategies are 
currently being discussed. A recent review of available data on 
BCG revaccination before these data were released led WHO to 
conclude that the existing evidence, prior to the completion of the 
BCG revaccination PoI trial did not support BCG revaccination 
policy13.
Unlike a PoR endpoint, however, it is unclear whether a PoI 
endpoint could serve as an indication for licensing for two rea-
sons: 1) only approximately 10% of Mtb-infected individuals 
ultimately develop active TB, so it is theoretically possible that 
infection prevention, should it be demonstrated, is only occur-
ring in persons who would otherwise control their Mtb even 
without vaccination and not develop TB disease; and 2) the 
prevention of infection endpoint depends on assessments such 
as the tuberculin skin test (TST) or interferon-gamma release 
assay (IGRA) whose specificity and sensitivity are not 100%.
Both the PoI and PoR approaches pose a risk when used as 
experimental endpoints towards the development of a PoD vac-
cine, as it remains unknown whether these other endpoints 
actually predict efficacy for PoD in the general population. It 
is possible that preventing disease, preventing infection and 
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preventing recurrence of disease in cured patients may require 
fundamentally different immunological responses, thereby lead-
ing to positive or negative results that would not be predictive 
of a positive PoD outcome.
The current moment represents a critical juncture for TB vac-
cine development. In 2018–2020, clinical efficacy data are 
scheduled to be released from five phase 2b proof of concept 
studies: Vaccae, H4/BCG revaccination (data subsequently 
released and described above), M72/AS01 (data subsequently 
released and described below), Dar901 and VPM1002. Results 
from these trials will paint a clearer picture as to the potential of 
the global vaccine candidate pipeline, optimal paths for future 
TB vaccine design and development strategies, and the predic-
tive ability of current animal models. Ideally, candidates that 
demonstrate efficacy will also enable discovery of candidate 
correlates of protection, with potential to substantially streamline 
further TB vaccine development.
Many challenges must be addressed to develop a success-
ful TB vaccine. Mtb represents a complex pathogen that has 
evolved with humanity for tens of thousands of years, allow-
ing it to evolve in such a way as to survive the normal range of 
immune responses directed against it. The absence of a known 
correlate of immune protection against TB in humans has 
hampered vaccine discovery and development, as has the inability 
to assess the predictive nature of animal challenge models given 
the lack of vaccine efficacy data in humans to date. Late stage 
efficacy trials, particularly phase 3 trials for efficacy and safety, 
are long and expensive, as are subsequent phase 4 programs, 
together representing a potential disincentive for biotechnol-
ogy and pharmaceutical companies to expend resources given 
the relatively high risk of failure and expectations of limited 
commercial returns. Moreover, the TB vaccine field remains 
severely underfunded, particularly given the potential impact 
of a vaccine in curbing the TB epidemic and the global soci-
etal cost of TB, estimated at $19.2 billion in 2017, including 
a $7.2 billion cost for treatment and control activities and 
$12 billion indirect costs to the economies1.
Despite these challenges, however, it is becoming clear that 
developing new TB vaccines is an achievable goal. The partially 
protective effect of BCG, capable of preventing up to 80% of 
cases of severe, disseminated TB in infants and young children, 
provides important supportive evidence of this point. Additional 
evidence comes from the 90% of Mtb-infected persons who are 
capable of controlling their infection throughout their lives 
without developing disease; and the intriguing examples of indi-
viduals at high risk of Mtb infection who, when assessed for Mtb 
infection by TST or IGRA, demonstrate transient positivity on 
repeated assessments before reverting to a consistently negative 
state, a situation with unclear clinical significance but which 
has been interpreted by some as evidence of early immuno-
logical containment of Mtb infection and a reduced risk of TB 
disease14–17. Examples of individuals with lifelong exposure 
to Mtb, through household or occupational contact, for exam-
ple, who never convert their TSTs or IGRAs, may represent 
another example of natural immunity to Mtb that a vaccine could 
be able to replicate or improve upon18.
Accordingly, there are reasons for optimism in TB vaccine 
development. New strategic directions include diversifying the 
pipeline to explore candidates that generate immunity beyond 
CD4+ Th1 T-cells, including non-conventional, cellular immu-
nity and trained innate immunity19; assessing new routes of 
vaccine administration, including aerosol and, possibly, intra-
venous approaches; investigating the extent to which antibody 
generating vaccines may contribute to protection afforded by the 
current, cell-mediated immune generating candidates; and uti-
lizing new tools for vaccine candidate R&D, including posi-
tron emission tomography-computerized tomography (PET-CT) 
scans20 and bar-coded Mtb strains21 permitting ultrasensitive 
assessments of animal challenge models, and a potential con-
trolled human infection model (CHIM) for Mtb22,23. These new 
strategic directions in TB vaccine development add to the sense of 
optimism and excitement in the field.
e. Modeling impact according to vaccine profile
Mathematical modeling techniques provide useful estimates 
of the future impact of vaccines in development. A review of 
twenty-four mathematical modeling studies applied to the case 
of TB vaccine development and implementation, provide insights 
relevant to decisions concerning the optimum age of vaccination, 
the most impactful vaccine indication, and the minimum duration 
of vaccine effect, efficacy levels and implementation strategy 
needed to have a meaningful impact on the TB epidemic8.
Mathematical models suggest that, in low- and middle-income 
countries overall (LMICs), targeting adolescents and adults for 
TB vaccination campaigns will result in a greater and faster 
impact on the TB epidemic before 2050, than would targeting 
infants7. In aging, reactivation driven, epidemics like China, a high 
proportion of TB disease occurs in older adults; accordingly, tar-
geting adolescents and younger adults would not be expected 
to have an important effect in controlling TB before 2050, as 
compared to a vaccine with administration targeted to older 
adults.
Vaccinating infants with an improved TB vaccine would rep-
resent an important public health benefit over the long term, 
but would not have as great an impact before 2050 as would an 
adolescent/adult vaccine, mainly because infants and young 
children are not an important source of Mtb spread. Accordingly, 
the public health impact of an infant vaccine would be delayed 
until adolescence, when the burden of Mtb infection, and the 
possibility of spreading Mtb to others, increases. Moreover, 
an infant vaccine would need to demonstrate higher efficacy 
and/or longer durations or protection than a vaccine adminis-
tered to adolescents and adults to have an important, and cost 
effective, effect on public health7. Mathematical modeling of 
the impact of vaccinating infants extends to the year 2050. 
Beyond that, there is too much uncertainty to draw conclusions 
with confidence.
Modeling suggests that, before 2050, a PoD vaccine would have 
a greater and faster effect on controlling Mtb spread than would 
a PoI vaccine8. Even if a 100% efficacious PoI vaccine were 
to be developed and made available by 2025, the target date for 
TB vaccine introduction set by the WHO End TB Strategy, a 
Page 6 of 28
F1000Research 2018, 7:1732 Last updated: 03 DEC 2018
PoD vaccine also would need to be utilized if the 2035 End TB 
Strategy targets were to be met. The body of available mathemati-
cal modelling literature is at equipoise as to whether the effect 
of a PoD vaccine would be greater if administered to persons 
who are not yet infected with Mtb as compared to those who are 
latently infected, with three models predicting that a pre-infection 
vaccine would provide the greatest impact, while four suggest 
that a post-infection vaccine would have a greater effect on TB 
control. More recent modelling evidence, specifically exploring 
this issue suggests that in aging, reactivation driven epidemics 
like China, because over the modelled vaccination time frame most 
TB disease is predicted to occur among the elderly population, 
a PoD vaccine administered to persons latently infected with 
Mtb would have greatest and most rapid impact24.
While a PoR vaccine would be expected to contribute to TB 
control efforts, no mathematical modeling of the public health 
effect specifically of a PoR vaccine as yet has been undertaken.
Mathematical modeling exercises reinforce the intuitive conclu-
sion that a vaccine with greater efficacy and a longer duration 
of effect will have greater benefit than those with lesser degrees 
of efficacy and durations. In addition, modeling has suggested 
that a PoD vaccine with protective efficacy as low as 20%, 
and duration as short as 5 years, administered to adolescents 
and adults, could have an important and cost-effective effect in 
controlling the spread of Mtb in LMICs7. Vaccines with 
shorter duration of effectiveness could be compensated for by 
higher efficacy or performing more frequent mass vaccination 
campaigns, to the extent that resources and logistical realities 
might permit.
In summary, mathematical models of TB vaccine effect suggest 
that, for maximum impact before 2050, the optimal new TB 
vaccine would prevent Mtb disease (although in transmis-
sion-driven epidemics a vaccine preventing infection would be 
useful), would be targeted for use in adolescents and adults, and 
would have a duration of effect of at least five years. Modeling 
also emphasizes that optimal vaccine strategies to control TB 
may differ between countries based upon the segment of the 
population that is driving the epidemic and so should be tailored 
accordingly. Future modeling exercises are needed to explore 
the effect of a PoR vaccine, to get a clearer picture of optimum 
vaccine strategies in other high burden countries such as India 
and South Africa, to assess the impact and cost-effectiveness 
of vaccines on controlling the spread of multi-drug resistant 
TB (MDR-TB) and extensively drug resistant TB (XDR-TB), 
to gauge the impact of new vaccines in combination with the 
scale up of other interventions, and to assess the impact of TB 
vaccine administered as immunotherapeutic agents in persons being 
treated for active TB.
2. Vaccines for BCG replacement
a. The BCG vaccine’s profile and role in public health
Optimally, certain information should be known when attempt-
ing to develop a vaccine, such as the immune mechanisms 
necessary and sufficient to protect against infection and/or 
disease, the antigens that stimulate a protective immunological 
response, the antigen delivery platforms best capable of evoking 
a protective response in a safe and acceptable manner, and 
confirmation of the protective mechanisms in human clinical 
efficacy studies. Currently, none of this information is 
available for TB vaccines. Accordingly, additional information 
must be sought and utilized to justify and guide the TB vaccine 
development effort.
There is some skepticism about whether a truly effective 
vaccine can be developed against TB. We know that about 90% 
of people infected do not develop disease and that individuals 
who are immunocompromised have 10-fold greater risk, 
establishing the importance of protective immune responses. One 
interesting piece of information comes from an observational 
clinical study published in the mid-1930s2. In this study, nurses 
entering service in a TB hospital in Norway were assessed for 
their rate of TB based on their TST status prior to entering this 
service. This study revealed that nurses who were TST posi-
tive had a 96% reduced risk of developing clinical TB than did 
the nurses who were TST negative, with an annual TB rate of 
4% to 5% observed in the TST-negative nurses, suggesting a 
meaningful degree of protection against TB disease stemming 
from latent TB infection (LTBI). A later analysis of 14 studies 
confirmed this result, with LTBI found to be 78% protective 
against TB disease, even though Mtb infection, in itself, poses a 
risk for developing TB3.
The bacille Calmette-Guérin (BCG) vaccine represents the only 
successful vaccine as yet developed for TB. BCG is derived 
from Mycobacterium bovis, a bovine mycobacterium passaged 
230 times in the Pasteur laboratory in Lyon by Drs. Calmette 
and Guérin between 1908 and its first human use in 1921. 
It has since become the most widely used vaccine in human 
history, with well over 3 billion doses administered; currently, 
more than 100 million children annually are administered 
BCG within hours or days of birth, representing 89% of the 
annual global birth cohort. BCG provides excellent protection 
in infants against disseminated miliary and meningeal TB, 
particularly serious forms of the disease with high mortality rate 
(RR 0.1; 95% CI 0.01 - 0.77)25.
While evidence of BCG-induced protection against miliary 
and meningeal TB in infants is widely accepted, the degree to 
which BCG prevents pulmonary TB in infants, children and 
adults remains controversial. In the past, some of the differ-
ing results has been attributed to the variety of BCG strains 
currently being used globally, yet in meta-analyses of clinical 
trials utilizing different BCG strains, no statistically significant 
difference in efficacy has been identified25. An observational 
study determined that LTBI provides better protection than BCG 
vaccination against developing pulmonary TB in adults2, 
while a meta-analysis of randomized clinical trials of BCG 
efficacy in children with known exposure to Mtb identified a pro-
tective effect against acquiring Mtb infection of 27% (RR 0.73, 
95% CI 0.61 – 0.87) and a protective effect against developing 
active TB of 71% (RR 0.29; 95% CI 0.15 – 0.58)26.
Overall, the results of studies of BCG effectiveness, beyond 
prevention of miliary and meningeal TB in infants, has been 
marked by extraordinary variability and inconsistency, with 
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rates of BCG-induced protection varying from 80% to totally 
non-protective at any age group. A number of hypotheses 
have been advanced to explain this variation and relative lack 
of effectiveness. These include differences in key antigens 
between Mtb and BCG, including the absence in BCG of the 
important Mtb RD1 and ESX genetic regions; differences in the 
potency of the various BCG strains in use globally; and interfer-
ence from exposure to atypical environmental mycobacteria. 
Mycobacterial exposure, generally in countries closer to the 
equator, has the potential to confound assessing the efficacy of 
BCG or any new vaccine candidate in populations whose immune 
systems have been engaged by cross-reacting mycobacterial 
antigens.
Another unknown about BCG is the extent to which the vac-
cine persists following infant vaccination. Anecdotal reports of 
two teenage boys in France who developed disseminated BCG 
following immune-suppressive treatment for cancer suggest the 
potential for long, latent duration, a factor that may influence 
the activity of new TB vaccines.
BCG administration has changed since its first delivery to an 
infant whose mother had active TB in 1921. Initially, BCG was 
administered orally, where most organisms were presumed to 
be killed by stomach acid. Calmette, however, observed bacil-
lemia following oral administration, leading later to a switch 
of BCG administration to the intradermal (ID) route. Experi-
ments with intravenous (IV) administration of BCG to rhesus 
macaques in the early 1970s demonstrated significantly greater 
protection against pulmonary and hematogenous TB follow-
ing aerosol Mtb challenge than in macaques receiving ID BCG27. 
Recently, there has been renewed interest in the possibility of 
greater effectiveness of BCG if administered in a way that per-
mitted broader diffusion in the lungs – via inhalation of an aero-
solized preparation of BCG28, or systemic dissemination such 
as would occur following IV administration29. Preclinical appli-
cation of such approaches offers the opportunity to understand 
the immunological mechanisms that convey heightened protec-
tion in, for example, Mtb challenge models utilizing non-human 
primates such as rhesus macaques and to explore possible 
clinical applicability. While early, exploratory clinical trials of 
inhaled BCG have not identified safety concerns30, assuring 
that an IV route is sufficiently safe for humans is likely to prove 
challenging.
While BCG generally is regarded as safe, hematogenous 
dissemination of 1% following ID administration has reported, 
mainly in infants with HIV infection and other forms of 
immunosuppression31. For this reason, BCG is contraindicated 
for use in immunosuppressed infants. The potential for develop-
ing serious complications, including death, following uncontrolled 
hematogenous dissemination when administered to immuno-
suppressed infants represents an important rationale driving 
the need for replacing BCG with a safer TB vaccine that can be 
administered to all infants, regardless of HIV infection status 
or immune competence.
Improved understanding of Mtb and BCG pathophysiology has 
led to potential paths forward for improving BCG. As BCG is 
missing the RD1 and ESX genetic regions present in Mtb, one 
possible future approach is to replace them in genetically modi-
fied BCG strains. Additionally, it is known that Mtb is capable 
of escaping the macrophage endosome and thereby has its anti-
gens processed in the cytosol, inducing cytotoxic T-lymphocyte 
responses, and that antimicrobial peptides derived from cyto-
toxic lymphocytes (CTL) are able to kill Mtb within infected 
macrophages in vitro. While BCG is incapable of escaping the 
endosomes or generating a significant CTL response, a BCG-
derived TB vaccine, VPM1002, has been genetically manipu-
lated to permit its escape from the endosome, resulting in 
cytosolic antigen processing32. The extent to which this altera-
tion may improve BCG efficacy for use in both infants and adults 
is under active investigation.
Finally, developers of vaccines targeted at replacing BCG in 
infants will need to take into consideration the effects of BCG 
unrelated to protection against TB. BCG vaccination has been 
demonstrated to provide protection against leprosy, and this con-
stitutes one of the bases for BCG recommendation13. Studies of 
BCG-associated protection against Buruli ulcer disease, however, 
have demonstrated mixed results33,34. Improvement in all-cause 
mortality in LMICs has also been reported35. Additionally, BCG 
has been demonstrated to provide a 70% protection from super-
ficial bladder cancer36. Ultimately, investments will need to be 
made to support clinical studies to fully evaluate all candidates 
intended to replace BCG, as well as any new TB vaccine.
b. VPM1002
VPM1002 is a recombinant BCG (rBCG) vaccine being devel-
oped both as a replacement for BCG vaccination in infants and 
as a TB vaccine in adolescents and adults32. In VPM1002, a lis-
teriolysin gene has been added to the BCG genome and a urease 
gene has been deleted, permitting the rBCG to escape the 
macrophage lysosome, which occurs in Mtb infection but not 
with BCG. Processing VPM1002 antigens in the cytosol results in 
activation of the AIM2 inflammasome, inducing autophagy of the 
VPM1002-infected macrophage and stimulating innate immu-
nity in a manner not seen with BCG. The manufacturing 
process for VPM1002 also offers the prospect of avoiding the 
frequent, global shortages of BCG, as it is manufactured using 
fermentation media, with a 50-liter batch yielding approximately 
5 million doses.
The safety and tolerability of VPM1002 has been assessed in 
a recently-concluded phase 2 trial of HIV-exposed and HIV-
unexposed infants in South Africa; data from this trial is due 
for public release in Q3/2018. A phase 3 trial, comparing 
VPM1002 safety and efficacy to BCG in 10,000 South African 
infants is scheduled to begin imminently, with completion targeted 
for 2021.
c. MTBVAC
MTBVAC is the only attenuated vaccine derived from Mtb 
currently in clinical trials. To create this vaccine, two sta-
ble deletions were made in the genome of an Mtb clinical 
isolate, selected so as to avoid laboratory subculture: deletions 
of the phoP gene, needed to control the transcription of key Mtb 
virulence genes permitting its survival in host cells; and fadD26 
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gene, required for the synthesis of cell surface lipids that play a 
critical role in Mtb pathogenicity37. As MTBVAC is derived from 
a clinical Mtb strain, and only carries two specific deletions in 
its genome, the vaccine candidate possesses 519 more epitopes 
(1603 epitopes) than currently used BCG (1084 epitopes)38. Chal-
lenge experiments in mice demonstrated improved protection 
by MTBVAC as compared to BCG, with protection associated 
with a T-cell mediated response to two Mtb-specific antigens, 
CFP10 and ESAT6, present in MTBVAC but absent in BCG39.
MTBVAC is primarily being developed to replace BCG as a 
priming immunization against TB. The rationale for target-
ing infants includes the need for an improved vaccine over BCG 
given the remaining burden of pediatric TB, and the oppor-
tunity to deliver vaccination to a population without prior 
sensitization to BCG, Mtb or environmental mycobacteria, 
thereby avoiding potential “masking” or “blocking” effects on 
MTBVAC-induced protection.
A phase 1a study, conducted in BCG-unvaccinated adults liv-
ing in an area not endemic for TB, demonstrated the safety 
and immunogenicity of MTBVAC40. MTBVAC currently is 
being further assessed for safety and immunogenicity in new-
borns in a phase 1b dose escalation study conducted in a TB-
endemic region of South Africa, with a safety arm in adults. 
Vaccination of newborns enrolled in this study was completed in 
September 2016, with one-year follow-up in September 
2017. A phase 2a dose-defining safety and immunogenicity 
study of MTBVAC in 99 HIV-unexposed newborns in TB-
endemic regions of sub-Saharan Africa is being planned. This 
study is also intended to build capacity for future, later-stage 
evaluations of this vaccine starting in 2018.
In addition to use in infants, MTBVAC is being assessed for 
use in adolescents and adults previously vaccinated with BCG. 
Preclinical studies of revaccination of guinea pigs with MTB-
VAC have demonstrated improved protection compared to that 
conferred by BCG41. Initiation of a phase 1b-2a, double blind, 
randomized, BCG-controlled, dose-escalation safety and immu-
nogenicity study in 120 healthy South African adults, ages 
18–50 years, with and without LTBI is being planned for the 
latter half of 2018.
3. Vaccines for adolescents and adults (phase 2 and 
beyond)
a. VPM1002
In addition to its development as a vaccine to replace BCG in 
infants, VPM1002 also is being developed as a TB vaccine for 
adolescents and adults. A phase 2b/phase 3, randomized, double- 
blind, placebo-controlled trial to assess VPM1002 vaccine effi-
cacy in preventing recurrence of TB in adults recently treated 
and cured of active TB (PoR) is underway in India. Sample size 
calculations for this study assume a 5% rate of TB recurrence in 
the placebo arm and a 50% reduction of TB recurrence among 
subjects in the VPM1002 arm during a 12-month follow-up 
period. Two thousand persons (1,000 in each arm) will be 
enrolled to achieve 80% power at a 5% significance level, 
with a 10% estimated drop-out rate. A phase 3 study to protect 
against TB disease among household contacts of persons with 
active TB is planned to begin in late 2018.
b. M72/AS01E
M72/AS01E, the GSK proprietary candidate vaccine, con-
sists of a fusion protein expressing two immunogenic Mtb 
antigens: Mtb39A, a membrane-associated protein expressed 
early in the Mtb life cycle, putatively identified as an immune 
evasion factor; and Mtb32A, a constitutively expressed secreted 
protein and a putative serine protease, combined with the adju-
vant system AS01E containing monophosphoryl lipid A (MPL) 
and QS21 in a liposomal suspension, geared to promote a Th1 
immune response42. Key components of the target product pro-
file (TPP) for M72/AS01E include preventing TB in adults and 
adolescents; an efficacy level of 70% or greater (no minimally 
acceptable level of efficacy has yet been set by the developers); 
a clinically acceptable safety profile, including safety for use 
in HIV-infected individuals; acceptability for co-administration 
with widely recommended adolescent vaccines when adminis-
tered in a 2-dose regimen 1 to 6 months apart; and a duration of 
protection of 10 or more years. The possible need for boosters 
will be explored.
The M72/AS01E candidate vaccine was first introduced into 
humans in 2004; clinical development has been conducted 
in collaboration with Aeras. M72/AS01E has been tested for 
safety and immunogenicity in 12 completed phase 1 and phase 
2 studies. The vaccine has been tested in adults who were PPD 
negative, PPD positive43, HIV negative44, HIV positive on 
antiretroviral therapy (ART)45, and HIV positive not receiving 
ART44. Adults during or after TB treatment were the focus of 
one phase 2 trial. Adult trials have been conducted in non-
endemic and endemic TB settings. The vaccine has also been 
assessed in adolescents in South Africa and in infants in The 
Gambia46. Overall, M72/AS01E was found to be safe and well 
tolerated in the recruited populations, with more reactogenicity 
noticed in subjects with active TB disease. The vaccine induced 
a high-magnitude, M72-specific CD4+ T-cell polyfunctional 
response (IFN-gamma, IL-2, TNF-alpha and CD40L) that persisted 
for more than 1 year.
A phase 2b proof of concept efficacy study in approximately 
3,500 IGRA positive, HIV-negative adults in clinics in South 
Africa, Kenya and Zambia, in which enrollees were followed 
up for three years for the occurrence of TB disease, has been 
concluded. Subsequent to the meeting reported here, results 
have been released47. The study demonstrated 54% (90%CI 
14%–75%) vaccine efficacy against pulmonary tuberculosis, 
during a period of follow-up of approximately 2 years. Increased 
reactogenicity (local reactions and flu-like symptoms) were more 
common in M72/AS01E vaccine recipients relative to placebo 
recipients, but no unexpected safety concerns were raised. Sec-
ondary analyses suggest vaccine efficacy does not appear to 
wane over the follow-up time, and may be a function of age, 
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but secondary signals should be interpreted with caution, 
as they are based on small numbers. The study is ongoing, with 
final results expected to be released in 2019.
c. H56:IC31
The H56:IC31 vaccine is an adjuvanted fusion protein, con-
sisting of three highly immunogenic Mtb antigens – Ag85B, 
ESAT-6 and Rv2660c – and adjuvanted with the Valneva IC31© 
adjuvant48. ESAT-6 is a premiere virulence-associated antigen 
highly expressed throughout all stages of infection while Rv2660c 
is a stress-induced antigen, strongly associated with latent TB 
infection. The IC31 adjuvant consists of ODN1a, a TLR9 ligand, 
and a stabilizing molecule that helps establish depot formation. 
The central immunologic strategy of this vaccine is to gener-
ate long-lived, Th1-type T-cell immunity. The vaccine is being 
developed by the Statens Serum Institute (Denmark), with mul-
tiple partners including Valneva, GmBH (Austria), Aeras, the 
South African TB Vaccine Initiative (SATVI), The European 
and Developing Countries Clinical Trials Partnership (EDCTP) 
and the Research Council of Norway.
H56:IC31 is being developed to prevent TB disease in adoles-
cents, adults and the elderly, as well as in children and infants, 
to prevent recurrent TB, and to shorten drug treatment for active 
TB and serve as adjunctive immunotherapy to patients with active 
TB, including those with drug-resistant TB. The targeted efficacy 
is ≥50%, with a duration of protection of ≥10 years. The vaccine 
is administered via intramuscular injection (IM) in two doses.
Phase 1 and phase 2 studies of safety, immunogenicity and dose 
finding have been completed in IGRA+ and IGRA- adults, IGRA- 
adolescents, and in adults completing treatment for active TB. 
Thus far, the vaccine has demonstrated no safety concerns. Immu-
nogenicity studies demonstrate a strong induction of ESAT-6 
responses both in IGRA+ persons and in those completing 
treatment for active TB48. Antibody responses also were noted in 
a proportion of vaccinees. Along the therapeutic track, an ongo-
ing, open label phase 2a trial in Norway is assessing the safety 
and immunogenicity of H56:IC31 given three months into active 
TB treatment as adjunctive immunotherapy with and with-
out additional COX2-inhibition. A major phase 2 PoR trial of 
H56:IC31 is being planned and will enroll 900 persons being 
treated for pulmonary TB; 450 receiving vaccine and 450 admin-
istered a placebo. Vaccine will be administered within the last 
month of planned completion of 6 months of drug treatment, 
with follow-up for 12 months following vaccination. The trial is 
designed to have 80% power to detect 50% vaccine efficacy with 
a significance level of 0.05, given an expected TB recurrence 
rate of 4% per year in unvaccinated controls. Twenty-three 
endpoints (recurrent TB) are expected over the 1 year of follow-
up. The primary objective of this trial is to accelerate the devel-
opment of H56:IC31 toward a possible phase 3 PoR trial and 
licensure for this indication. Capacity building and studies of 
mechanisms of reactogenicity, immunogenicity and efficacy 
also represent important components of this trial. Enrollment 
in this trial is planned for Q3 2018.
d. ID93/GLA-SE
ID93 is a fusion of four Mtb antigens with diverse roles that 
are recognized by T-cells isolated from Mtb-exposed individu-
als and lack human sequence homology49. The fused proteins in 
the ID93 vaccine include Rv1813, an antigen up-regulated under 
hypoxic conditions; Rv2608, the PPE protein, probably asso-
ciated with the Mtb outer-membrane; and Rv3619 along with 
Rv3620, both included among the EsX protein family of 
secreted virulence factors. GLA-SE is a synthetic TLR-4 agonist 
adjuvant, formulated in a squalene oil in a water nano-emulsion. 
GLA-SE has been demonstrated to be safe in humans, with thou-
sands of doses delivered, induces a TH1-biasing immunological 
response, and production is readily scalable.
ID93/GLA-SE is being developed for two indications: as an 
immunotherapeutic agent to improve the outcome of drug treat-
ment for active TB, and as a prophylactic vaccine to prevent infec-
tion with TB. Proof of principle for the ability of ID93/GLA-SE 
to enhance TB treatment has been demonstrated in mice, guinea 
pigs and non-human primates, where immunotherapeutic vaccina-
tion with ID93/GLA-SE in combination with multidrug therapy 
was associated with a polyfunctional Th1 response, improved 
bacterial clearance and reduced pulmonary inflammation50. 
Protection against progression to pulmonary TB in a guinea pig 
Mtb challenge model was observed for more than 1 year51.
Two phase 1, and one phase 2a clinical trial of ID93/GLA-
SE in healthy adults in the United States and South Africa have 
been completed. These trials, assessing safety, immunogenic-
ity and dosing approaches, have included persons not vacci-
nated with BCG, BCG vaccinated individuals, and persons who 
are IGRA-, IGRA+ and those with active TB disease. Results 
from these studies demonstrated the induction of a broad, 
polyfunctional T-cell response, an increase in multi-functional 
antibodies, and robust CD4+ T-cell responses in IGRA+ 
adults, suggesting that the vaccine boosts the immune response 
to natural infection49. The phase 2a trial, in which vacci-
nation occurred at the end of TB treatment, demonstrated 
encouraging CD4+ T-cell and antibody responses to vaccination. 
These studies also demonstrated an acceptable safety profile 
for ID93/GLA-SE in more than 200 research participants. Sev-
eral new Phase 2 studies of ID93 / GLA-SE are being prepared. 
A Phase 2a study to evaluate the safety, immunogenicity and 
preliminary efficacy of ID93 / GLA-SE in preventing infec-
tion with TB among high-risk health care workers in Korea is 
being planned. Additionally, two Phase 2b clinical trials of ID93 
/ GLA-SE to evaluate the vaccine as an immunotherapeutic 
adjunct to multidrug therapy have received funding. In 
India, a collaboration with the All India Institute of Medi-
cal Sciences will administer the vaccine to patients undergoing 
multidrug therapy for both drug-sensitive and drug-resistant TB. 
In South Africa, plans are being developed for an expansion of 
the Phase 2a prevention of recurrence study, with the intention to 
advance administration of the vaccine proximally towards the ini-
tiation of TB therapy, beginning at the completion of therapy and 
moving as early as two months after chemotherapy has started.
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e. RUTI ™ for adjunctive immunotherapy
RUTI is being developed as an immunotherapeutic agent for 
adults, intended to improve the efficacy and shorten the duration 
of drug treatment for cases of active TB, including drug-
resistant TB52. RUTI is made of cell wall fragments of Mtb 
formulated in a liposome suspension and is administered 
subcutaneously (SQ) in a single dose. Preclinical experiments 
demonstrate an added effect compared to Mtb drug treatment in 
reducing Mtb colony counts in mice, a reduction in regrowth 
rate as far out as week 28 following Mtb challenge in guinea 
pigs, and a diminished TB relapse rate in a paucibacilli 
murine model of TB.
Two clinical trials have been completed. The initial study, a 
phase 1 safety, immunogenicity and dose-ranging trial in 24 
healthy adults in Spain, triggered a vaccine-specific immuno-
logical response against several Mtb antigens, without signifi-
cant toxicity, supporting further development53. The second study 
was a phase 2 safety, immunogenicity and dose ranging trial 
in 48 HIV+ and 48 HIV- persons with LTBI in South Africa52. 
These studies demonstrated a good cellular polyantigenic 
response after a first injection of 25 mcg in both HIV- and HIV+ 
participants and elicited a long-term memory surrogate response 
compatible with a prophylactic potential already observed in 
animal models.
Future development will focus on utilizing RUTI as an adjunct 
to drug treatment in patients with MDR-TB, to prevent disease 
relapse after treatment for drug-sensitive TB, and to shorten the 
drug treatment regimen. A phase 2a trial to evaluate the safety 
and immunogenicity of RUTI in MDR-TB patients favorably 
responding to standard MDR-TB treatment is underway, with 
a plan for a subsequent phase 2b-phase 3 pivotal clinical trial in 
this population.
f. Vaccae™
The Vaccae™ vaccine is a heat-killed preparation of Myco-
bacterium vaccae, an NTM closely related to M. obuense54. 
Vaccae™ has been licensed in China as adjunctive immunotherapy 
for drug treatment of active TB. A pooled analysis of data from 
trials of the M. vaccae vaccine suggested some potential utility 
when used as an immunotherapeutic adjunct to drug treatment of 
active pulmonary TB. In 2012, the Chinese government approved 
the initiation of a clinical trial to test the candidate vaccine 
for prevention of the occurrence of tuberculosis in subjects 
with LTBI. A 10,000-person, placebo-controlled phase 3 study 
involving a 6-dose vaccination regimen was initiated. Reten-
tion rates in the trial were high, and more than 100 cases of TB 
occurred during the study. The efficacy and safety data from 
this completed study have not yet been released.
4. Diversifying TB vaccine platforms
a. Importance of immune characterization
Most advanced vaccine candidates share one important commo-
nality: they were selected for development on the basis of their 
ability to induce interferon-gamma producing T-cells obtained 
from vaccinated animals and individuals upon in vitro myco-
bacterial antigen stimulation. Very little evidence, however, 
is available to confirm the full scope of the critical immune 
responses necessary to control TB disease and Mtb infection, 
including the potential roles of CD8+ T cell responses, tissue 
resident memory T-cells, mucosal-associated invariant T (MAIT)-
cells in the lungs and B cell activation. Studying these and other 
diverse immune responses generated by current and future vaccines 
likely will be critical to advancing TB vaccine development in 
a more efficient and effective manner55.
Many of the more diverse immune responses likely to be impor-
tant in controlling TB in humans may not occur in small animal 
models, or even in non-human primates. Accordingly, “experi-
mental medicine” studies, involving 20–30 people and designed 
to gain a better understanding of a vaccine’s ability to gen-
erate the types of immune responses that may be critical in 
controlling TB, particularly those occurring in lung paren-
chyma, in bronchus-associated lymphoid tissue, and in the pul-
monary mucosa, will be important to conduct. It also remains 
important to engage in parallel, more empirical vaccine effi-
cacy and safety studies designed to inform immune mechanisms 
of protection. Collection of biospecimens in clinical studies 
in support of planned or future immunological studies, using 
the best technology available, is critical to permit retrospective 
analyses of correlates of protection once clinical protection is 
demonstrated by a vaccine under development.
While it is important to develop and utilize a TB vaccine as 
soon as possible, it also is important to remember that evidence 
of TB disease has been discovered in humans occurring as far 
back as 9000 BCE56. Given this lengthy history between TB and 
humans, it is critical that we take the long view when develop-
ing vaccines for TB; whether we develop a vaccine by 2035 or by 
2050 represents a rounding error from the perspective of human 
history.
b. Cytomegalovirus (CMV) recombinant vaccines against 
TB
Mtb represents a particularly difficult challenge for vaccine devel-
opers as it appears to both evade host immunity and modulate it 
in its favor. Accordingly, a successful TB vaccine likely will have 
to hit Mtb infection hard and early, in a manner that prevents 
Mtb from taking control of the host immune response directed 
against it. A CMV-vectored vaccine strategy offers the poten-
tial for accomplishing this by generating “effector-memory” 
T-cells prepositioned in the lungs, at sites of early pathogen 
colonization57.
The strategic rationale for selecting a CMV vector for a TB 
vaccine resides in its unique ability to elicit and maintain robust, 
effector-differentiated CD4+ and CD8+ T-cell responses in organs 
outside lymphoid structures, including the respiratory tract. 
Experiments with rhesus CMV (RhCMV) in rhesus macaques 
(RMs) demonstrate that RhCMV vectors expressing foreign 
antigens manifest the critical biological properties needed 
to generate effector-memory T-cells in a safe manner. These 
properties include the ability to super-infect rhesus already 
infected with CMV, and to persist indefinitely despite robust 
anti-CMV immunity in naturally CMV seropositive animals; 
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the capacity to elicit and indefinitely maintain high frequency, 
“effector differentiated” T-cell (T effector and T tissue-resident 
effector) responses in mucosal sites, lymphoid tissues and paren-
chymal organs; and the ability to maintain immunogenicity 
despite profound attenuation. In particular, genetically attenuated 
(ULb’ mutated) RhCMV vectors (68-1 RhCMV) demonstrate 
an unexpected and unusual capability to elicit CD8+ T-cell 
responses that entirely, and broadly, target novel epitopes 
restricted by MHC-E and MHC-II58.
The primary rationale for a CMV-vectored TB vaccine is to 
generate tissue effector T-cells capable of immediate intercep-
tion of Mtb-infected macrophages at sites of initial lung infec-
tion prior to the initiation of the substantial immune system 
modulation caused by Mtb necessary to permit Mtb survival 
and replication. Two RhCMV-TB vaccines have been created 
thus far, one expressing nine Mtb proteins across four different 
RhCMV vectors, the other expressing six Mtb proteins as a sin-
gle polyprotein from one vector. Two RhCMV-TB efficacy 
pre-clinical assessments studies of these vectors, utilizing a 
low-dose (25 colony forming unit (CFU)) challenge of Erdman 
strain Mtb, have been completed57. In the first study, the extent 
of lung, non-lung and overall TB disease at one year follow-
ing Mtb challenge was significantly reduced in RhCMV-TB 
vaccinated NHPs as compared to unvaccinated and BCG vac-
cinated controls. BCG vaccination prior to RhCMV-TB vaccina-
tion appeared to reduce the efficacy of the experimental vaccine. 
In the second study, no TB disease was detected via lung CT 
scans in 13 of the 27 CMV-TB vaccinated animals, as compared 
to unvaccinated controls where all demonstrated TB involve-
ment of lungs and lung-draining lymph nodes. While all 
unvaccinated RMs demonstrated both pulmonary and extra- 
pulmonary TB at necropsy, no gross or microscopic TB was 
found in the 13 RMs with CT scans that did not demonstrate TB 
disease. Moreover, 10 of these 13 were Mtb culture negative. 
Taken together, these studies demonstrated unequivocal protec-
tion—defined as a finding of no granulomatous disease at necropsy 
(41%) and a significant reduction in TB disease (32%)—in 73% 
of vaccinated RMs. Comparisons between different CMV-TB 
constructs also determined that efficacy is not dependent on 
unconventional MHC-II and MHC-E restricted CD8+ T-cell 
responses.
Future steps in the development of these promising vaccine 
constructs will include optimization of the vector backbone 
and the gene inserts and validation of the final CMV-TB vector 
design in NHP challenge experiments. The first phase 1 clinical 
trial of a CMV-TB vaccine is targeted for 2020.
c. Novel emerging vaccine technologies: mRNA-based 
vaccines
Messenger RNA (mRNA) vaccines represent a non-viral deliv-
ery system of vaccine antigens that offers the potential of stimu-
lating both the innate and adaptive immune systems in a manner 
that provides a balanced cellular and humoral antigen-specific 
response59. Factors spurring interest in mRNA vaccines include 
their ability to express complex membrane proteins, induce both 
CD4+ and CD8+ T-cell responses (unlike many protein anti-
gens), permit efficient re-dosing given the absence of anti-vector 
immunity and their non-cell based manufacturing platform, 
allowing more rapid production than for vaccines requiring cell 
culture-based manufacturing processes. Potential cons to utilizing 
mRNA vaccines include the reactogenicity of the delivery 
systems currently in use which limits the mRNA dose and 
antigen multiplicity, and cost-of-goods considerations given target 
price points for a TB vaccine.
No mRNA vaccine as yet has been developed for TB. mRNA 
technology, however, is a potentially attractive vaccine strat-
egy against TB in light of the platform’s ability to induce 
potent T- and B-cell responses, including polyfunctional T-cell 
responses that home to the lungs, the ability of these vaccines to 
co-express multiple antigens, and the potential to deliver these 
vaccines via ID, IM, subcutaneous (SC), intranasal (IN), aerosol 
(AE) and intravenous (IV) routes, based on the formulations. 
Limitations to their use for TB include the non-persistent nature 
of antigen expression and the limited number of antigens that 
can be included in each vaccine. Ultimately, the identification 
of a set of Mtb antigens that offer the possibility of effective 
protection would be needed to stimulate greater interest in 
applying mRNA vaccine technology to TB prevention efforts.
d. New candidates for live attenuated TB vaccines
Live, attenuated vaccines (LAVs) are pathogens missing genes 
responsible for producing virulence factors or key metabolic 
enzymes, with the absence of these genes resulting either from 
rational design or randomly through passage. When creating 
LAVs as vaccine candidates, developers must maintain a bal-
ance between attenuation and virulence, as too much attenuation 
may impair the ability of the candidate to generate a sufficiently 
protective immune response, while insufficient attenuation 
would raise safety concerns.
Major advantages to using LAVs include their ease and low 
cost of production, their longer persistence and the ability to 
stimulate both adaptive and innate immune responses, thereby 
obviating the need for adjuvants with the establishment of a 
long-term, comprehensive immunity. This stands in contrast to 
inactivated whole cell vaccines that primarily induce neutralizing 
(humoral, antibody-based) immunity with minimal mucosal 
and innate immune stimulation and little generation of 
cell-mediated immunity (CMI); and recombinant vector vaccines 
that primarily generate CMI with minimal innate and mucosal 
immunity, and with little to no humoral immunity60.
The primary disadvantage to LAVs is a concern about their safety. 
The potential for reversion to wild-type virulence remains a 
possibility for organisms attenuated through the deletion of one 
or a few virulence genes. Additionally, LAVs that behave in an 
attenuated fashion in persons with normally functioning immune 
systems may prove dangerous and even deadly if administered to 
persons with compromised immune function.
Rational deletion of Mtb virulence genes represents an excit-
ing approach to creating a new generation of TB vaccines. One 
attenuated Mtb vaccine concept results from the deletion of 
MosR (Regulator of Mycobacterial Operons of Survival, Rv0348) 
that plays an important role in Mtb survival during infection61. 
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C57BL/6 mice vaccinated subcutaneously with the ΔMosR 
vaccine demonstrated a low level of vaccine persistence in 
lung and spleen for at least 16 weeks following vaccination. 
After challenge with the highly virulent Mtb Beijing strain, 
improved protection over BCG-vaccinated mice was observed; 
in some animals Mtb could not be detected at 60 days after 
challenge, with benign-appearing lungs on histopathological 
examination62.
In order to reduce the chance of reversion to a virulent, wild-
type state, another gene deletion, involving the echA7 gene, 
has been introduced. A plan is underway to combine these 
two deletions into the same Mtb strain and assess the potential 
utility of this construct as a TB vaccine.
e. A systematic antigen discovery approach in humans
The current approach to TB vaccine development suffers from 
three shortcomings: 1) it has focused mostly on a narrow set of 
candidate TB antigens which may have suboptimal activity in 
protecting against TB; 2) it has focused on generating classi-
cal, CD4+ T(h1) cells, which may be essential but not sufficient 
to generate an optimally protective response; and 3) has not 
taken into account recently emerging evidence suggesting a role 
for traditionally “ignored” cells, such as B-cells, in generating 
immunological protection against TB. Accordingly, explor-
ing the role of unconventional T-cells and T-cell responses, 
such as donor unrestricted T-cells (DURTS), mostly CD8+ 
T-cells restricted by CD1, MR1, HLA-E, TCR-gamma-delta; 
non-IFN-γ producing T-cells; and the role of non-T-cells will be 
critical to future TB vaccine development efforts55,63.
The current global clinical pipeline of TB vaccine candidates 
utilizes a limited number of the approximately 4,000 Mtb anti-
gens. A critical question is whether the optimal antigens are 
being selected for inclusion in protein subunit and recombinant 
viral vaccines. In a large phase 2b trial of the MVA85A vaccine 
in South African infants, the vaccine did not provide signifi-
cant additional protection above BCG vaccination64. A possible 
explanation for this outcome is that Ag85A, although highly 
immunogenic, may not have been the right antigen given that its 
expression is downregulated later in infection and may not be 
presented sufficiently by infected cells.
An emerging hypothesis in defining optimal antigens to include 
in a TB vaccine is to identify Mtb antigens expressed during 
infection in the lungs of susceptible individuals65–67. To iden-
tify such antigens, an unbiased, genome-wide antigen discovery 
approach was taken, utilizing Mtb RNA isolated from the lungs 
of four different mouse strains, ranging from hyper-susceptible 
to TB (C3H/FeJ mice, the sst1 strain) to genetically resist-
ant (C57Bl6 mice). Utilizing a genome wide qRT-PCR platform 
developed at Stanford University, Mtb genes were selected that 
were persistently and highly expressed in vivo (in vivo expressed 
– IVE-TB – genes) at multiple time points following AE Mtb 
infection. 194 IVE-TB highly expressed genes were identi-
fied and 50 further selected based on ranking in the top 15% 
during infection; hyperconservation with wide HLA coverage 
and/or homology with Mycobacterium leprae. Many of these 
IVE-TB antigens were found to induce strong CD4+ T central 
memory and CD8+ T-cell responses in PBMCs from long-term, 
latently Mtb infected individuals, and were recognized by both 
T- and B- cells67.
Almost all Mtb antigen discovery approaches have mainly relied 
on IFN-γ measurements. Recent evidence, however, suggests 
that IFN-γ only contributes marginally to overall protection 
against TB in the lungs of mice68. An investigation of other 
responses, including proliferative and cytokine profiles besides 
IFN-γ, in a cohort of healthy Dutch individuals with PPD and/or 
ESAT6+CFP10 in vitro responses, and in a cohort of Norwegian 
individuals with LTBI, demonstrated that many IVE-TB antigens 
induce cytokines other than IFN-γ69.
These new approaches may lead to novel classes of antigens 
with promising vaccine potential. Additionally, B-cells play a 
critical, underappreciated role in conferring immunity to human 
TB70,71. B-cells may provide an important, novel target for TB 
vaccination, but Mtb antigens that activate B-cells have not 
been extensively studied as yet.
f. Antibody-generating vaccines for TB
It has long been appreciated that T-cell responses are critical in 
controlling TB. T-cells do more than direct CMI responses, how-
ever, as they also provide a crucial link to humoral immunity 
based on B-cell responses.
Experiments in mouse models of Mtb infection demonstrate 
that depleting B-cells decreases mouse survival following Mtb 
exposure, while B-cell depletion followed by B-cell restora-
tion returns survival to the degree observed in control mice, 
suggesting an important role for B-cell responses in control-
ling TB71,72. Moreover, histopathological studies in Mtb-infected 
humans and NHPs demonstrate aggregates of B-cells proximal 
to pulmonary granulomas, with B-cell laden tertiary germinal 
centers surrounding the granulomas73,74. Antibody-deficient 
mice also demonstrate a greater degree of viable Mtb in both 
lungs and spleen, and a marked decrease survival after infection 
with Mtb75. Passive transfer experiments with the monoclonal 
antibodies anti-lipoarabinomannan (LAM) and anti-HspX (directed 
against the 16 kD protein on Mtb outer membranes expressed 
during times of mycobacterial stress, including within granulo-
mas) resulted in improved survival (with anti-LAM antibodies)76 
and decreased lung Mtb CFUs (with HspX antibodies)77 in 
mice following Mtb challenge. These experiments provide 
additional evidence that antibodies limit Mtb infection. Improved 
mouse survival also was seen following administration of 
monoclonal antibodies directed against the mycobacterial heparin-
binding hemagglutinin (HBHA), with no effect on diminishing 
lung Mtb CFUs but with a marked decrease in spleen Mtb CFUs, 
suggesting an effect on decreasing Mtb dissemination78. Addition-
ally, the particular isotype of antibody makes a major difference 
in the ability to control Mtb, with IgA monoclonal antibodies 
having a larger effect than IgG1 antibodies79.
Most clinical studies of TB vaccines have not studied the role 
that antibodies may play in contributing to prevention of TB. 
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Accordingly, little thought has gone into defining vaccine-
induced antibody target product profiles (TPPs). In creating 
an antibody TPP for TB vaccines, it is important to recall that 
antibodies do much more than recognizing and blocking infec-
tion via pathogen neutralization. By binding to antigens on 
the surface of infected cells, antibodies play crucial role in 
stimulating a broader and more effective immune response, 
including the inducement of cytokine secretion to recruit cells 
such as dendritic cells and T-cells involved in mediating CMI, 
inducing autophagy in infected cells, and prompting innate 
immune responses including the recruitment of neutrophils, natural 
killer (NK) cells, monocytes and phagocytes.
Advances in systems serology assays now permit qualified and 
validated approaches to assessing antibody qualities and functions. 
Studies of TB patients utilizing systems serology have 
discovered that qualitatively different TB-specific antibodies 
are induced and distinct innate immune recruiting profiles are 
manifest in persons with LTBI as compared to those with active 
TB disease80. Antibodies play a key role in creating these differ-
ences, as antibodies expressed in persons with latent infection 
help stimulate innate immune responses by attracting dendritic 
cells to macrophages infected with Mtb, resulting in dendritic 
cell-mediated activation of innate immune responses. In particu-
lar, antibodies expressed in LTBI prepare the immune system to 
kill Mtb-infected cells, a signal sent via glycosylation patterns 
on the Fc domain of antibody molecules that were naturally 
modified during Mtb infection to access different innate immune 
functions81. Identifying the Fc glycosylation patterns that result 
in enhanced innate immune responses to TB provide a poten-
tial target for vaccine developers attempting to selectively 
induce such antibodies via vaccination.
Antibodies also play a unique antimycobacteriological role by 
identifying cells infected with Mtb and restricting Mtb survival. 
Non-classical killing mechanisms triggered by antibodies 
include enhancement of opsinophagocytosis, lysosomal matu-
ration, and inflammasome activation via a metabolic rewiring of 
macrophages, resulting in enhanced restriction of Mtb growth.
Clinical trials of vaccine candidates provide important oppor-
tunities to profile the quality of antibodies generated by these 
vaccines. Additionally, utilizing adjuvants offers an opportunity 
to generate many distinct antibody responses, resulting in the 
potential of rationally choosing adjuvants to more specifically 
stimulate the types of antibody responses that may be optimal 
in contributing to the control of TB. Accordingly, it will be 
critical to continue the clinical assessment of TB candidates 
and to build into these trials the opportunity to assess antibody 
responses as well as CMI.
Four hypotheses have emerged to explain the possible role of 
antibodies in contributing to the control of Mtb infection and 
TB disease. The first hypothesis involves restricting the extent 
of initial Mtb infection in and around the alveolus by blocking 
Mtb physically, by inducing complement-mediated Mtb kill-
ing, and by stimulating enhanced phagocytic activity against 
Mtb. The second proposed mechanism involves balancing 
inflammation resulting from Mtb infection, mainly by redirect-
ing pathologic innate immune activity in a way that reduces 
corresponding immunopathology. The third proposed mecha-
nism involves regulation of granulomas, including prevention 
of granuloma formation (in light of the emerging theory that 
granulomas are used by Mtb to more efficiently spread infection 
via attraction of susceptible macrophages) and the clearance of 
Mtb-infected cells. Finally, antibodies may enhance dendritic cell 
and T-cell antigen presentation and regulation, through signals 
sent by specific Fc glycosylation patterns.
Studies of antibody responses in LTBI populations, individu-
als who appear to be resistant to Mtb infection despite ongoing 
exposure, and persons participating in TB vaccine trials or 
in experimental medicine studies, utilizing more aggressive 
serological sampling techniques such as plasmapheresis, will be 
critical to advance the understanding of the potential roles played 
by antibodies in controlling TB. Using this information to 
design vaccine strategies that stimulate both humoral and CMI 
responses effective in controlling TB represents an important 
new strategy in TB vaccine development.
g. Diverse T-cell responses against Mtb
An important characteristic of a vaccine-stimulated immune 
response to Mtb is the ability of T-cells to recognize an Mtb-
infected cell via receptors that are highly conserved in humans. 
Most vaccines currently being developed do this through “clas-
sical” HLA-I or HLA-II restricted antigen presentation. Donor 
unrestricted T-cells (DURTS) represent different types of T-cells 
that interact with human antigen-presenting cells (APCs), 
including dendritic cells or macrophages, through mechanisms 
other than classical HLA-I or HLA-II restricted antigen pres-
entation. Examples of restriction molecule ligands associated 
with DURTS include: CD1a, b, c molecules, which present lipid 
and glycolipid moieties and bind CD1-restricted T-cells, includ-
ing Type I and Type II natural killer T-cells (NKT cells); MR1, 
which presents riboflavin metabolites and interacts with mucosal-
associated invariant T-cells (MAITS); and HLA-E, a highly 
conserved receptor that recognizes a diverse array of peptide 
ligands, binds to HLA-E-restricted T-cells and helps to medi-
ate natural killer-cell killing82. Although our understanding of 
DURTS ligands is still relatively superficial given that this is a 
young field of investigation, the potential applicability to TB 
vaccine development is great given that virtually all of the types 
of antigens presented by these ligands can be found in Mtb.
Studies of DURTS suggest that they contribute to protective 
immunity, with MR1 restriction involved in responses against 
Mycobacterium bovis via BCG vaccination83, and Klebsiella 
pneumoniae84,85, and both CD186 and HLA-E87,88 mediated 
responses contributing to Mtb control. It is not yet clear, however, 
if these are memory responses that can be generated through 
vaccination. Additionally, the duration of such responses is not 
known.
MR1-restricted responses are highly conserved in mammals 
and do not diverge across mammal species. MR-1 interacts with 
MAITS as sensors of the metabolome via riboflavin metabolites, 
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but also through other, as-yet-unidentified molecules89. In stud-
ies of patients with TB, a dramatic enrichment of MAITS 
was found in samples obtained from bronchoscopies as com-
pared to peripheral blood, with selective enrichment of certain 
T-cell receptors (TCRs) identified in the bronchoscopically- 
obtained samples, suggesting antigenic discrimination. This find-
ing led to the discovery of a novel class of MR1 ligands called 
photolumazines. Experiments with synthetic photolumazines 
suggest that there is immunological memory underlying MR1-
mediated antigenic recognition that could be harnessed in a 
TB vaccine90.
CD1-restricted T-cells recognize glycolipid antigens91,92. They 
represent an intriguing area of study given the presence of known 
antigenic glycolipids in Mtb, although the absence of group 1 
CD1 molecules in mice increases the difficulty of assess-
ing the importance of CD1-restricted immune responses in 
protecting against Mtb. Additionally, it is not yet known whether 
immunologic memory can be imparted to CD1-restricted 
T-cells.
HLA-E restriction encompasses presentation of both peptidic and 
non-peptidic antigens, and initially was identified as an inhibi-
tor of recognition between NK cells and T-cells. Subsequently, 
however, HLA-E-restricted T-cell clones have been found to 
manifest antimicrobial properties, including the inhibition of 
intracellular Mtb growth93. This inhibition appears to be mediated 
both by generating cytolytic properties in the T-cells, and by 
inducing a cytokine profile from these T-cells that resemble a 
Th2 phenotype. Additionally, gamma-delta cells, specifically 
γ9δ2 cells, have been found to be expanded following 
vaccination with BCG94 with further investigations suggesting a 
role in controlling intracellular growth of Mtb95.
Further elucidation of the role of DURT-mediated immune 
control of Mtb will most likely depend on the development of 
fit-for-purpose animal models, particularly mouse models, engi-
neered to assure the relevance of DURT response assessments. 
An example of this approach is the development of a humanized 
transgenic mouse model which expresses group 1 CD196.
A critical question regarding the potential for targeting DURTs 
through vaccination is whether DURTs have memory. If they 
do, and if durable expansion and preferential recall responses 
to these novel ligands can be elicited through vaccination, then 
DURTs could be harnessed directly as a potentially powerful 
vaccination strategy. If they are not capable of developing an 
anamnestic response but, instead, function more as adjuvants, 
then DURTs could be manipulated to help facilitate the acquisi-
tion of adaptive immune responses to Mtb. Ultimately, it will be 
necessary to develop fit-for-purpose animal models, identify 
the appropriate immunogens, develop techniques to formulate 
the ligands and create relevant animal challenge models to explore 
the potential of harnessing DURTs as a vaccination strategy 
against TB.
h. Immune correlates and signatures of protection
Biomarkers that can reliably and accurately predict clinical out-
comes of diseases are invaluable to vaccine development efforts. 
Biosignatures, custom-made combinations of biomarkers, 
offer the potential to enhance the predictive power of a sin-
gle biomarker. Principally, biosignatures can be useful both 
in selecting promising vaccine candidates for more advanced 
development, while rejecting those with a reduced probability 
of ultimate success. They also can be used to more finely tailor 
the selection of individuals being enrolled into clinical trials, 
thereby reducing the cost and increasing the efficiency of such 
trials. Thus far, studies exploring blood, urine or breath of 
persons with asymptomatic Mtb infection have not identified 
a biosignature predictive of the development of active TB 
disease.
The development of advanced, data-dense assessment tech-
niques, including transcriptomics, proteomics, metabolomics has 
enhanced the opportunity to identify biosignatures of the pro-
gression of Mtb infection to active TB disease. Transcriptomes, 
which require samples of whole blood, combined with compu-
tational modelling, currently represent the most widely studied 
biomarkers in TB. Taken together, small signatures, utilizing 
three to four transcripts and assessed via decision trees or other 
computational methods, have resulted in a biosignature which 
discriminates active TB disease from LTBI with 85–90% sen-
sitivity and specificity97,98. Signatures comprising 16 transcripts 
now can predict the development of active TB in individuals 
with LTBI 6–12 months prior to a clinical diagnosis99. Further 
refinement of algorithms led to a predictive signature com-
posed of only two transcript pairs which detect risk of active 
TB up to one year prior to clinical diagnosis of TB in different 
regions of the African continent100. Metabolomics represents 
an under-researched area, particularly given that such studies 
can be run utilizing serum or plasma rather than whole blood, 
reducing the complexity and cost of sample collection and 
storage. Initial studies applying metabolomics to diagnosing 
active TB101 have been promising, and are being investigated 
to provide a 6- to 12-month prognosis among individuals with 
LTBI.
It now appears clear that both metabolomic and transcriptomic 
signatures can be harnessed for diagnosing incipient TB, and 
for providing a 6- to 12-month prognostic window regarding 
the likelihood of developing TB among those with LTBI. 
While this has immediate relevance to decision-making around 
initiating preventive drug therapy before the development of 
clinical disease, it also provides the opportunity to stratify indi-
viduals in clinical trials of vaccines. Using these techniques to 
identify and selectively enroll LTBI individuals who are at risk 
of developing TB in an efficacy trial of a vaccine to prevent 
TB disease could considerably reduce the numbers of study 
participants required, shorten the clinical trial duration and 
greatly reduce cost by several orders of magnitude, assuming that 
these signatures could be utilized at reasonable cost and speed.
Important future directions in biosignature research relevant 
to TB vaccine development will be to identify signatures of 
vaccine efficacy and signatures of vaccine safety. While studies 
of BCG responses can lay the groundwork for this102,103, 
ultimately this effort will depend upon identifying an initial, 
partially efficacious TB vaccine through ongoing clinical trials, 
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and having had the foresight to bank sufficient blood and serum 
specimens from trial participants to permit biomarker studies104. 
This further emphasizes the need to continue to conduct clini-
cal efficacy trials of TB vaccines, and to invest in the collection 
of biological specimens from the participants. Only through 
efforts such as this will unexpected findings be identified that 
potentially could result in a major acceleration of novel TB 
vaccine development.
5. Use of models in translational TB vaccine research
a. Small animal models
Effective natural immunity against developing TB exists, given 
that 90–95% of Mtb-infected individuals fail to develop active 
TB disease1. While this rate of natural immune protection is dif-
ficult to improve upon, it will be necessary to do so to con-
trol the global TB epidemic. In order to effectively manipulate 
the human immune response to TB we require new and diverse 
vaccine candidates and we need to correlate the immune 
responses induced by these vaccines with the degree of protection 
conveyed. Small animal models of Mtb infection can assist in this 
effort105.
Small animals can be experimentally manipulated to provide 
a reproducible challenge model capable of screening vaccine 
modulated vertebrate immune responses to limit Mtb growth in 
the lung. Mice and guinea pigs (GPs) have been the main small 
animal species utilized for assessing vaccine candidates105. 
Mice are inbred, easily manipulated, inexpensive, and there are 
extensive reagents for immunological studies. Both mice and 
GPs provide the opportunity to compare vaccine efficacy by 
assessing bacterial load and survival following Mtb challenge. 
GPs are susceptible to very low dose Mtb challenge and can 
be used for natural transmission or repeated low- and ultra-
low-exposure models. It may be feasible to utilize GPs in a 
post-exposure model as well. The pulmonary pathology of Mtb 
infection in GPs is similar to that of human primary TB106.
Potential indications for TB vaccines in humans include preven-
tion of TB disease (PoD), prevention of relapse or reinfection 
following treatment (PoR), and prevention of Mtb infection 
(PoI). To discriminate between potential PoD vaccines, TB 
challenge in vaccinated small animals provides a direct measure 
of an anti-mycobacterial host response as well as the opportunity 
to detect pathological outcomes. For meaningful PoD efficacy, 
the optimal outcome in a small animal would be to reduce bac-
terial burden below the level of detection. Assessment of PoR 
vaccines can also be performed in small animals, but due to 
the variability in outcomes, large numbers of mice are 
required107. A PoI vaccine model is not currently optimized for 
small animals, although studies of GPs in a natural exposure 
environment could provide proof of concept17.
Other factors, such as the nutritional status of the animals, corti-
costeroid stress, the animal microbiome and the genetic back-
ground of the animal can influence the outcomes of challenge 
experiments. The development of “collaborative cross” (CC) 
mice, a multiparent panel of recombinant inbred mouse strains 
derived from eight founder laboratory strains108 provides a striking 
demonstration of the effect of genetics on response to vacci-
nation and Mtb challenge, as shown by the differential effect of 
BCG vaccination on the genetically diverse CC mouse strains109. 
Additional factors that can affect outcomes are the bacte-
rial strain selected for the challenge110 and the bacterial dose. 
While these external factors should be controlled for during 
vaccine screening, they also provide the potential for testing 
vaccine efficacy under a variety of conditions.
The revised TBVI/Aeras stage gate criteria make experiments 
in small animals an explicit part of TB vaccine candidate 
development110. Stage gates B and C include calls for explora-
tion of safety, immunogenicity and protection in small animal 
species. In this context, protection is defined as being repro-
ducibly and statistically better at preventing TB disease than 
BCG or a relevant benchmark. Ultimately, it will be important to 
determine the extent to which vaccine protection demonstrated 
in small animal Mtb challenge experiments is corroborated by 
data from experiments in NHPs and in human clinical trials.
Assessment of TB vaccine candidates in small animal models 
can be compromised by suboptimal experimentation as well as 
inappropriate or over-interpretation of experimental outcomes. 
It is important therefore to state that there are no ‘bad’ models, 
only inappropriate interpretation of the results.
b. The role of a continuous exposure natural transmission 
animal model for vaccine development
Standard animal challenge models of Mtb infection differ 
from natural infection in a number of ways, including chal-
lenge with a higher Mtb exposure than the very low exposures 
that characterize natural infection; a single challenge as com-
pared to the repeated exposures associated with natural infection; 
and exposure to a naturally occurring form of Mtb rather than 
laboratory-grown strains. Laboratory-grown strains are usually 
treated with mild surfactants such as Tween™ that prevent clump-
ing and permit accurate quantification of dose, but strip the 
outer lipid capsule off of Mtb and thereby potentially alter its 
immunogenicity111. To overcome these issues, a human to guinea 
pig (GP) continuous natural exposure model was established17. 
In this model ambient air from a specially built patient unit 
caring for individuals with active TB is removed via negative 
pressure and exhausted into a neighboring facility harboring 
GPs, with each GP receiving an average 4-month exposure to 
the stream of air laden with naturally occurring, uncultured 
Mtb. A total of 362 GPs have been exposed over 12 years: 91 
(25%) remained free of infection while 271 (75%) became infected 
as determined by tuberculin skin test (TST) conversion. Of 
the 271 TST converters, 53 (15%) experienced a reversion of 
their skin test, with 33 (9%) of the reverters subsequently 
reconverting, presumably due to re-infection. Only 54 (15%) of 
the infected or re-infected GPs went on to develop TB disease.
TST reversions following initial conversion occurred in 15% of 
convertors, more commonly than had been anticipated. Repeat 
TST conversion following initial reversion was completely 
eliminated by irradiating the air from the patient unit, sug-
gesting that the reversion and repeat conversion events were 
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due to subsequent re-infection rather than non-specific reactions 
to non-viable Mtb. Examining the time course of TST reactions 
in these GPs over time revealed a pattern suggesting repeated 
Mtb exposures and subclinical infections, many which initially 
resolve but which ultimately result in established infection 
and disease.
These findings illustrate the critical role that repeated rein-
fection with Mtb appears to play in the overall course of TB 
pathogenesis. A correlative finding was described in a study 
of TB patients in a Siberian hospital, where admission into 
the hospital with drug-sensitive TB (DS-TB) translated into a 
six-fold increased risk of developing drug-resistant TB (DR-TB), 
as compared to patients with DS-TB treated as outpatients, due 
to re-infection with DR-TB while in hospital112.
Preventing disease due to re-infection with new Mtb strains 
represents an important target for TB vaccines but a difficult 
one to assess given the absence of a biomarker for Mtb reinfec-
tion. A continuous exposure, natural transmission animal model 
that mimics human exposure in many high-burden settings, such 
as the human to GP exposure model described here, can serve to 
address this need. Vaccine suppression of transient TST or 
IGRA conversions seen in this model may represent an impor-
tant target. A clinical study also is being implemented to assess 
the role that BCG vaccination may play in preventing IGRA-
negative, BCG-naïve individuals who will be working in 
TB-endemic areas from acquiring Mtb infection. This investi-
gation, called the Tuberculosis Immunization to Prevent Infec-
tion (TIPI) study, will enroll 2,000 USA-based healthcare and 
humanitarian workers (e.g., Peace Corps workers, persons 
entering service with Doctors without Borders or other NGOs). 
Half will be will vaccinated with BCG, and IGRA conversion 
rates will be compared against the unvaccinated arm over the 
period of exposure. Blood samples also will be collected to 
permit an assessment for correlates of immune protection if a 
difference in IGRA conversion rates is found between vaccinated 
and unvaccinated cohorts.
c. Simian models of TB
Non-human primates (NHPs) represent the closest model of 
human Mtb infection113. NHPs demonstrate the full spectrum of 
TB, including active disease, latent infection and reactivation114,115. 
TB-induced pathology in NHPs is reflective of human pathol-
ogy, including caseating granulomas and other granuloma types, 
as well as cavitary lung disease115. Additionally, NHPs are immu-
nologically closer to humans than other animal models as they 
possess unconventional T-cell subsets, including CD1a-d and 
delayed type hypersensitivity (DTH) responses to BCG and 
TB113. Reagents and laboratory technologies are available for 
the detailed analysis of the immune system of macaques, a NHP 
species frequently used to study TB pathogenesis and in Mtb 
challenge experiments. Sequential sample collections from 
blood and mucosal sites also are possible, permitting time course 
studies of systemic and mucosal immunity that enable studies 
of biomarkers and immune correlates of protection.
Rhesus macaques, mainly of Indian origin, and cynomolgous 
macaques currently are the most common NHP species used 
to model Mtb infection and TB disease116. One major advance 
in improving NHP models of Mtb challenge applicable to 
vaccine candidate assessment has been the development and 
application of advanced, non-invasive imaging techniques to 
serially track disease progression in a sensitive and quantifiable 
manner. The simultaneous application of computerized tomogra-
phy (CT), which provides detailed images of internal structures 
and permits the quantification of pulmonary disease burden, in 
combination with positron electron tomography (PET), which 
demonstrates the spatial distribution of metabolic activity, 
thereby providing fundamental information relevant to TB 
pathogenesis, have proven valuable in assessing the degree of 
protection provided by newly-developed vaccine candidates20.
Another major improvement in NHP models of TB has been the 
development of low-dose Mtb challenge (<25 CFU) and very-
low-dose Mtb challenge (<10 CFU), doses that more closely 
approximate natural human exposure to Mtb than did the 
500–3,000 CFU exposures previously used. Additionally, the 
development of advanced tools for studying immune responses, 
permitting detailed studies of adaptive immune responses as well 
as assessments of diversified components of the rhesus immune 
response, have increased our understanding of NHP immune 
responses to vaccination and its effect on controlling an Mtb 
challenge before the candidate under study is selected for 
clinical evaluation.
As macaque populations demonstrate different responses to Mtb 
infection, it is important to select the rhesus species most rel-
evant to the target product profile of the candidate vaccine when 
designing challenge experiments. It is also important to consider 
the species in which the experiments have been done when 
attempting to draw comparisons between challenge studies. For 
example, cynomolgus macaques demonstrate a greater degree of 
disease control following Mtb challenge than do rhesus macaques, 
making the former potentially more representative of Mtb 
infection in adults, and the latter modeling Mtb infection in 
infants and young children, where de novo infection tends 
to have more serious consequences117. The ability to control 
Mtb infection also varies within species; among cynomolgus 
macaques, the Asian sub-species controls Mtb infection better 
than those of the Mauritian sub-species. Among rhesus macaques, 
Chinese rhesus control Mtb better than do those of the Indian 
subspecies. To further facilitate inter-study comparisons, a greater 
degree of harmonization and standardization of experimental 
methods must be achieved, including challenge strain selec-
tion, use of imaging, scoring gross pathology specimens and 
identifying priorities as to future experimental directions, such 
as assessing AE delivery of vaccines. This harmonization and 
standardization effort is underway within the Collaboration for 
TB Vaccine Development (CTVD), led by the Bill and Melinda 
Gates Foundation (BMGF). CTVD recommendations regard-
ing NHP-based study design for TB vaccine development have 
recently been published118.
d. Achieving sterilizing immunity in animal challenge 
models
Most TB vaccine candidates reduce Mtb CFU by ~1–1.5 logs 
in mice challenge experiments and are usually considered 
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sufficiently protective to merit further development if they result 
in a ~1 log improvement over the reduction seen by BCG. As 
even this degree of CFU reduction results in ~1×104 Mtb CFU 
in mouse lungs following a standard Mtb challenge experiment, 
the question is whether this is a sufficient degree of CFU 
reduction to suggest the potential success of the vaccine 
candidate. The acceptance of this degree of post-vaccination 
pulmonary Mtb CFU has been largely based on the idea that 
this may be the full extent of suppression that TB vaccines 
can produce in mice, given the “limited dynamic range” of the 
murine immune system. It is unclear, however, whether this 
assumption is correct, or whether sterilizing immunity, or 
something approximating this, can, in fact, be generated in 
mice through manipulations of murine immunity that might be 
achievable through vaccination.
The standard mouse model of vaccination and Mtb challenge 
calls for vaccination at time 0, permitting 30 days to pass to 
allow the generation of a memory response, and then administer-
ing an AE Mtb challenge. Subsequently, the degree of protection 
afforded by the vaccination, and the Mtb-specific T-cell 
responses are assessed.
Challenge studies in vaccine-naïve mice reveal that the pul-
monary accumulation of Mtb-specific T-cells during primary 
Mtb infection is delayed by approximately 21 days, with peri- 
granulomar B-cell follicles – inducible bronchus-associated 
lymphoid tissue (iBALT) – appearing at 24 days119. Vaccinat-
ing the mice with BCG accelerates the Mtb-specific T-cell 
response by one week, with these cells appearing in the pulmo-
nary parenchyma between 12–14 days following Mtb challenge 
and with iBALT appearing at day 17. In either case, Mtb is capa-
ble of establishing viable and progressive pulmonary infection, 
albeit with fewer organisms following BCG vaccination.
It is possible that the delay in appearance of Mtb-specific 
T-cell responses in the lungs may represent a critical bottle-
neck to developing effective TB vaccine-induced immunity, a 
bottleneck that could be overcome if Mtb-specific T-cells could 
arrive at the initial sites of infection earlier. To test this hypoth-
esis, dendritic cells (DCs) pulsed with Mtb antigens were 
transferred intra-tracheally one day before and then four days 
after AE Mtb challenge to mice that had received BCG vacci-
nation, and some of which had also received a mucosal boost 
with Ag85B administered intranasally. This DC transfer over-
came the TB vaccine bottleneck, resulting in the presence 
of Mtb-specific, cytokine-producing T-cells on the third day 
following challenge, inducing iBALT 8 days following Mtb 
infection, and resulting in rapid lung macrophage induction 
in the vaccinated mice120. The rapid vaccine-induced T-cell 
responses limited early Mtb growth, reducing Mtb CFU by 2 
logs or more over vaccinated animals that had not received the 
DC transfer, with Mtb undetectable in approximately 50% of 
the mice upon sacrifice on day 20.
The DC transfer proved to be more effective in inducing steri-
lizing or near-sterilizing immunity in mice that had received 
the mucosal Ag85A vaccine in addition to BCG, as compared 
to mice that only had received BCG. Gene expressions studies 
revealed that the gene expression signature of T-cells induced 
by the vaccines and antigen-pulsed DCs were enriched for the 
mucosal/airway phenotype. When the experiment was repeated 
using a multi-drug resistant Mtb strain as the challenge strain, 
however, sterilizing immunity was not achieved. Addition-
ally, endogenous, host DCs could be induced to generate 
near-sterilizing immunity through the administration of a select 
activation of innate mechanisms including CD103 and CD40 
pathways. Delivery of amph-CpG adjuvant and CD40 ago-
nist at the time of challenge, rather than through the transfer of 
pre-stimulated DCs also provided complete Mtb control, pro-
viding additional support for the possibility of stimulating this 
type of response through vaccination120.
Hints at the possibility of achieving near-sterilizing immunity 
against Mtb through vaccination have occurred with Mtb chal-
lenge experiments in rhesus macaques following vaccination 
with a CMV-TB vaccine construct48 and in mice following vac-
cination with the ΔMosR and ΔechA7 vaccine concepts62 or the 
ΔSigH vaccine concept121, all live, attenuated Mtb vaccines. If 
ongoing experiments continue to demonstrate sterilizing or near- 
sterilizing immunity with these or other vaccine concepts, this 
would suggest that a “limited dynamic range” of murine immu-
nity was not the explanation for the limited degree of Mtb 
suppression noted with other vaccine candidates. The location 
and timing of the vaccine-induced immune response to Mtb 
(i.e. developing an Mtb-specific immune response in the lungs 
within days of initial infection, rather than weeks) may be the 
keys to a successful vaccination strategy against TB.
e. Mucosal immunisation against TB
An inhaled TB vaccine makes intuitive and logistical sense for a 
number of reasons122. Primarily, an inhaled vaccine mimics the 
route of Mtb infection, and offers the potential for generating 
potent and durable mucosal immune responses and stimulating 
specialized, peri-bronchial lymphoid tissue that may be critical 
in controlling TB. Additionally, BCG, administered through 
the universally used ID route does not reliably protect against 
pulmonary TB. From a logistical perspective, inhalation rep-
resents a common route of drug delivery which is safe, feasible, 
needle-free and pain-free.
In a phase 1 clinical trial assessing the safety and immunogenic-
ity of 1×107 plaque-forming units (pfu) of the MVA85A TB 
vaccine administered via inhalation or ID in 22 BCG-vaccinated 
adults, Ag85A-specific CD4+ T-cell responses in fluid obtained 
via bronchioalveolar lavage (BAL) were found to be stronger 
after AE than ID administration30. Systemic Ag85A CD4+ 
T-cell responses were at least as strong after AE vaccina-
tion compared to ID administration. Additionally, no systemic 
anti-MVA vector IgG, IgA or IgM responses were detected 
following aerosol, but did develop following ID vaccination.
An important question to address when contemplating AE 
administration of TB vaccines is the safety of this administration 
strategy in persons with LTBI. This issue is being addressed in 
a phase 1 study of 15 persons with LTBI. Initial results from the 
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first two patients enrolled have not raised safety concerns thus 
far.
Additional studies of TB vaccines administered via the AE route 
are due to begin soon, including a first-in-human study com-
paring AE and ID administered ChAdOx1.85 (University of 
Lausanne, Switzerland) and aerosolized Ad585B (McMaster Uni-
versity, Canada). A clinical trial assessing the safety and immu-
nogenicity of increasing doses of BCG administered via the AE 
route based on encouraging protection and immunogenicity data 
in rhesus macaques, is ongoing, with no apparent safety issues 
raised and with encouraging, early immunogenicity data. It will 
be important to expand AE vaccination studies to sites endemic 
for TB to fully assess the safety, immunogenicity and efficacy of 
this vaccine administration strategy.
f. Alternative routes of BCG immunization
An effective vaccine against TB will likely need to 1) stimulate 
an effective and persistent T-cell response against multiple 
antigens; and 2) generate this response in the lung, the site of 
initial Mtb infection and TB-associated pathogenesis.
Live, attenuated vaccines are an attractive vaccine strategy 
when targeting infections that are comprised of thousands of 
potential antigens and whose control depends on an effective 
and persistent T-cell response at tissue sites, such as malaria, 
leishmania and tuberculosis. Accordingly, live attenuated vac-
cines are an effective approach for generating T-cell responses 
of high magnitude and antigenic breadth compared to other 
vaccine platforms. Additionally, live or live-attenuated vaccines 
can stimulate T-cell responses in locations critical to inducing 
protection depending on the route of administration, thereby 
providing a rapid immune response at the time of infection. For 
malaria, intravenous but not subcutaneous immunization of a 
live, attenuated whole sporozoite vaccine was shown to induce a 
high frequency of antigen specific T-cells in the livers of NHPs. 
Also, attenuated sporozoites administered IV but not SC could 
protect humans against experimental controlled challenge123. 
These data highlight the importance of the route of immuniza-
tion on an infection requiring tissue resident T cells to multiple 
antigens.
For TB, the route of vaccine administration also influences 
the sites of T-cell priming, and the location and strength of 
where tissue resident T-cells develop. ID or IM vaccination is 
the route by which BCG and all other TB vaccine candidates in 
phase 2 or phase 3 clinical trials are administered respectively. 
These routes primarily result in T-cell priming in local drain-
ing lymph nodes, a moderate circulating T memory (T
mem
) 
response and a weak lung-resident effector (T
eff) memory 
response, not an optimal situation when a rapid, lung-based T-cell 
response is needed for protection. Vaccines administered via the 
AE route result in local T-cell priming in the lung with a weak 
peripheral response121,124,125. Combining ID or IM administra-
tion with AE administration theoretically represents a strategy 
by which both lung T
eff memory cells, in combination with cir-
culating T
mem
, may be generated. With regard to AE delivery 
of vaccines, a series of NHP experiments with recombinant 
adenoviral-vectored TB vaccines encoding 2–4 antigens 
delivered via AE, generated robust T cell immunity in the 
lung, but did not result in greater protection against TB dis-
ease than with BCG given ID126. These data suggest that there 
was either lack of antigenic breadth presented by the vectors, 
poor quality of the virally induced responses, or unfavorable 
innate imprinting by the viral vectors associated with 
increased risk of Mtb infection. Based on the results of clinical 
trials with subunit vaccines given by IM route and the NHP 
data by the AE route, data suggest that vaccines with greater 
antigenic breadth and an alternative route of immunization may be 
optimal.
Vaccines administered IV result in T-cell priming in the spleen, 
and strong lung-resident T
eff memory and peripheral Tmem responses. 
Previous Mtb challenge experiments in NHPs receiving IV 
BCG administration resulted in greater protection than NHPs 
receiving either ID or a combination of ID and intra-tracheal 
BCG29,127,128. To directly assess the effect of various vaccine 
administration routes of a vaccine presenting a wide breadth 
of antigens, rhesus challenge experiments were conducted 
with BCG administered by ID, AE, IV and ID + AE, with a 
low-dose (15 CFU) challenge 6 months after immunization 
(BCG doses: ID – 5×105; AE – 5×107; IV – 5×107). Initial 
immunogenicity results from BAL samples demonstrated that 
IV BCG resulted in a significant increase in the frequency of 
TB-specific CD4+ T-cells, and CD8+ T-cells compared to the 
other administration routes. Additionally, IV BCG strikingly 
altered the proportion of T-cells and macrophages in BAL sam-
ples. At 16 weeks following vaccination, BAL samples after 
IV BCG demonstrated approximately 75% T-cells and 25% 
macrophages, while BAL obtained following the other routes 
of vaccine administration demonstrated greater than 75% 
macrophages and less than 25% T-cells at this time. Intravas-
cular staining of NHP lungs 10 months following vaccination 
demonstrated that 5–10% of cells in the lung parenchyma were 
T-cells, showing that IV BCG resulted in a long-lasting increase 
in pulmonary T-cells. The extent to which IV BCG actually 
persists in the lung, and the degree of protection against Mtb 
mediated by administration of BCG via the IV route, is being 
assessed.
g. Progress in clinical use of a controlled human infection 
model (CHIM) for vaccine testing
Controlled human infection models (CHIMs) have proven useful 
in vaccine development efforts, including vaccines for malaria, 
influenza and Salmonella typhi. Development of a CHIM for 
TB vaccine development would represent a major step for-
ward, given the uncertain predictive value of preclinical animal 
models, the lack of a validated immune correlate of protection 
and the value of detecting a signal of vaccine protection in the 
host species. A CHIM to support TB vaccine development could 
be used for vaccine selection as well as for immunobiology 
studies to inform basic knowledge gaps.
Developing a TB vaccine CHIM is challenging task given that 
virulent Mtb cannot be used in the challenge model for obvious 
ethical reasons. Accordingly, a major question facing TB vaccine 
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CHIM developers is whether Mtb can be manipulated to be safe 
enough to administer to volunteers. An additional question is 
whether BCG could be used either as the challenge organism 
or at least as an agent that would permit further clinical 
development of the clinical challenge model.
There are two key elements to developing a human challenge 
strain of Mtb for a CHIM: 1) developing a control system to 
elicit bacterial death; and 2) developing a system to detect viable 
Mtb in the days and weeks following challenge. When devel-
oping a system to control Mtb death, consideration must be 
given to the need to permit Mtb survival for multiple genera-
tions to permit an assessment of the effect of the vaccine on Mtb 
survival. At the end of the experiment, the killing control 
system must be able to eliminate all bacteria without relying on 
a lengthy course of antimycobacterial agents, and without the 
possibility of clinical relapse. Currently, three potential viabil-
ity control systems are being assessed. The first strategy relies 
on the degradation of non-canonical amino acids upon which 
Mtb auxotrophs are dependent for survival. Another approach 
is the insertion of “kill switches” into the Mtb genome, 
which are inducible through the administration of exogenous 
molecules, such as tetracycline, that induce a gene that codes 
for a mycobacterium-directed toxin. Thirdly, a strategy involv-
ing protein degradation targeting is under investigation. It is 
possible that more than one of these approaches could be used 
in combination to improve safety.
Detection systems for viable Mtb will need to measure the 
levels of bacterial load in the lungs without relying on a CFU 
count. Moreover, the detection strategy must be non- or mini-
mally invasive. Detection systems being assessed for a TB CHIM 
include skin detection of fluorescent proteins, serum detection 
of metabolites engineered to be expressed by the Mtb challenge 
strain, and breath detection of engineered volatile organic 
compounds.
Many questions regarding a CHIM for TB vaccine development 
remain to be answered, questions that will confront both CHIM 
developers and regulators tasked with assuring the safety of 
the mycobacterial control and detection strategies ultimately 
selected for the initial TB CHIM. Safety is paramount; ques-
tions regarding the confidence in the level of safeguards built 
into the Mtb challenge strain, and the potential for reversion to a 
virulent state, will need to be addressed. The duration of survival 
of a CHIM Mtb strain necessary to permit an adequate assessment 
of potential vaccine protection, and the level of sensitivity of 
detection that would need to be built into the system to permit 
these assessments remains unclear. Whether or not a vaccine 
effect can actually be detected via a CHIM strategy, and, if 
so, the types of TB vaccine for which this approach would be 
relevant, also remains unclear. Finally, the likelihood of regulatory 
acceptance of any Mtb CHIM is not yet known.
Given these uncertainties, a different CHIM strategy, based on 
a human intradermal (ID) BCG challenge, is being developed 
in parallel to CHIMs based on intrapulmonary Mtb administra-
tion. The rationale behind the ID BCG CHIM is based on the 
theory that an effective vaccine against BCG also should protect 
against Mtb. BCG vaccination has been found to suppress 
growth of an ID BCG challenge in mice, cattle and NHPs22,129,130. 
A pilot BCG challenge study has been conducted in which 
volunteers freshly vaccinated with BCG, and those who were 
BCG naïve, were administered BCG ID, with punch biopsies 
obtained at 1, 2 or 4 weeks following ID BCG administration23. 
PCR and culture assessments of the biopsy specimens demon-
strated a small but significant degree of protection. A similar 
study, in which MVA85A and BCG + MVA85A was assessed 
in addition to persons vaccinated with BCG alone, also revealed 
a statistically significant reduction of ID BCG as determined 
by culture and PCR of skin punch biopsies in persons receiv-
ing BCG or BCG + MVA85A as compared to placebo or 
MVA85A alone131.
Efforts are currently underway to develop a human AE BCG 
challenge model. Key issues in this effort are the safety and 
tolerability of BCG administered via AE and the ability to 
recover BCG in the bronchoalveolar lavage fluid (BALF). No 
safety concerns have been reported from the study to date. 
Early assessments suggest that the extent to which BCG can be 
recovered in BALF appears to be low, which may indicate the 
need to administer higher BCG doses.
In summary, work is ongoing to develop an attenuated, labelled 
Mtb strain for use in a human challenge study. An Mtb CHIM 
is approximately 3–5 years away from clinical use, and regu-
latory discussions regarding its development are ongoing. 
Work is progressing on ID and AE BCG challenge models. 
Overall, a CHIM to assess TB vaccine candidates is consid-
ered feasible. Ultimately, however, any CHIM developed for this 
purpose will require validation against field efficacy trials.
6. Perspectives from funders and global health 
organizations working on TB vaccines
a. Perspectives from the Bill and Melinda Gates 
Foundation
The BMGF represents the largest global funder of research 
and development efforts specifically directed at TB vaccine 
development. The BMGF approaches TB vaccine development 
from the perspective of four strategic objectives:
1. To understand the natural immune response associated with 
protection against infection and disease: Efforts are underway to 
better understand the workings of the granuloma, the histopatho-
logic signature of Mtb infection and disease132. Unexpected 
diversity of granulomas has been shown in infected NHPs, even 
within the same animal: some granulomas are sterile while 
others appear permissive for Mtb survival21,133,134. Ongoing 
research seeks to understand the immunological mechanisms 
underlying permissive and non-permissive granulomas, and 
correlating results with those found in human granulomas 
obtained from surgical resections. Prospective cohort studies 
focus on outlier populations, such as persons who do not develop 
Mtb infection despite presumed prolonged exposure to house-
hold contacts with active TB disease. Differences in host control 
between these persons and individuals who become infected are 
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being investigated. Smaller experimental medicine studies will 
address specific immunological hypotheses. Knowledge generated 
from these efforts should inform rational vaccine design.
2. To develop new vaccine concepts that exploit immuno-
logical diversity: The focus is on vaccination approaches that 
target unconventional (non-Th1) immunity82 and /or target 
the lung directly (e.g., mucosal vaccination)122. In addition to 
delineating immunity that occurs in the natural infection set-
ting, induction of “unnatural immunity,” will also be explored, 
i.e., immune responses not induced during natural infection 
and disease. An example of a vaccine that fits this strategy is the 
CMV-vectored TB vaccine, being developed by Louis Picker and 
colleagues at the Oregon Health Sciences University (OHSU), 
with major support from the BMGF57. Other examples of uncon-
ventional immunity targeted include those mediated by antibodies 
or B cells70, CD-1 restricted T cells135, and MAIT cells136.
3. To develop improved tools and infrastructure to support an 
efficient, iterative process to test vaccine concepts: The BMGF 
continues to refine the paradigm for testing vaccine candidates, 
to more efficiently test candidates in human studies, to use 
improved animal models for up selection of candidates, and to 
improve learning along the experimental pathway. The BMGF 
supports development of improved NHP models, primarily, in 
support of this goal.
4. To foster greater innovation, collaboration and coordination 
within the TB vaccine landscape: In support of this the BMGF 
has created the Collaboration for TB Vaccine Discovery (CTVD), 
an international network of scientists and experts dedicated 
to fostering innovation, cooperation, and collaboration in the 
up-stream TB vaccine discovery space. Further activities include 
improved alignment with other funders and exploring global 
portfolio management for clinical testing of vaccines through the 
use of stage gating.
TB vaccine discovery is in an early stage, lagging drug 
discovery efforts by at least 10 years. Accordingly, the BMGF is 
putting increased focused on the upstream space with the intent of 
learning more about Mtb pathogenesis, and the immune responses 
necessary to control TB disease and prevent established Mtb 
infection. This information will help guide more rational and 
efficient TB vaccine development in the future.
b. The Global TB Vaccine Partnership
The Global TB Vaccine Partnership (GTBVP) is a five-year-old 
initiative which is comprised of the leading organizations con-
ducting and supporting TB vaccine research and development. 
The goals of the GTBVP are to enhance communication between 
key members of the TB vaccine R&D community, as well as 
between members of the community and the public at large—
particularly public and private decision-makers responsible 
for allocating resources in support of critical global health issues 
– in an effort to attract new funding to this under-resourced 
initiative. The GTBVP is made up of a leadership forum, a tech-
nical advisory group and a communications group. Under the 
direction of the GTBVP, a document describing the current 
state of the TB vaccine development effort, as well as future 
directions in TB vaccine R&D, is being drafted. Current 
plans call for this document to be revised every two years to 
reflect the rapid changes occurring in this dynamic field.
c. Aeras
TB vaccine R&D efforts are extremely resource constrained, 
with the burden falling on a few donors. The human impact of 
the disease in terms of suffering and death, along with the $19.2 
billion annual cost in treatment, care and loss of productivity, 
is far out of balance with the small and inadequate investment 
currently being made in TB vaccine development and testing.
A lack of balance also exists in the nature of the partners involved 
in TB vaccine R&D, as support from non-profit organizations, 
such as the BMGF, and governments far outweigh the involve-
ment of commercial entities such as established pharmaceuti-
cal companies and smaller biotech companies. Additionally, 
the shortage of funding has resulted in a lack of academic 
partners and new researchers entering the field. Moving forward, 
it will be important to create incentives for industry to increase 
activity in TB vaccine development initiatives.
Balance also needs to be achieved between support of “upstream” 
(basic research and discovery) and “downstream” (assessments 
of vaccine concepts and candidates in animal challenge mod-
els and human clinical trials) efforts. Increasingly, the scarce 
research dollars that exist are flowing upstream at the expense 
of support for downstream initiatives, particularly clinical 
trials. It will be critical to continue to move forward with ani-
mal challenge studies and clinical trials utilizing a diversity of 
vaccine candidates and vaccine strategies, with a commitment to 
challenging dogma. It will be important to recognize, however, 
that TB vaccine development is challenging, and many efforts 
will lead to failure. Failure must be accepted if success is to be 
achieved.
d. European and Developing Countries Clinical Trials 
Partnership
The European and Developing Countries Clinical Trials Part-
nership (EDCTP) applauds the collaborative spirit that infuses 
the TB vaccine development field. An example of this is the 
collaboration between TuBerculosis Vaccine Initiative (TBVI), 
Aeras, the European Commission (EC), BMGF and EDCTP in 
developing stage gate criteria, designed to promote an efficient 
and coordinated approach to managing the TB vaccine portfo-
lio by selecting the best TB vaccine candidates and advancing 
them through development in an optimized and non-redundant 
fashion.
It is imperative to continue conducting clinical trials of TB vac-
cine concepts and candidates. To further this effort, the EDCTP 
will be supporting a number of clinical trials of TB vaccines 
in the upcoming years. Additionally, the EDCTP will help 
support development of a human challenge model for TB, given 
the potential utility of such a model in driving the TB vaccine 
development effort forward.
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e. The Stop TB Partnership, working group on new TB 
vaccines
The Stop TB Partnership exists to support the WHO in its 
efforts to eradicate TB. Key goals of the Partnership are to 
strengthen the capacity and research literacy of advocates, and 
to strengthen the advocacy literacy of researchers. Developing 
advocates for TB vaccine development must represent an essen-
tial component of any strategy geared to increasing funding for 
TB vaccine R&D efforts.
f. The Tuberculosis Vaccine Initiative
The TuBerculosis Vaccine Initiative (TBVI) is a non-profit foun-
dation that facilitates the discovery and development of new, 
safe and effective TB vaccines that are accessible and afford-
able for all people. As a Product Development Partnership 
(PDP), TBVI integrates, translates and prioritises R&D efforts to 
discover and develop new TB vaccines and biomarkers for glo-
bal use. TBVI provides essential services that support the R&D 
efforts of its consortium partners—50 partners from academia, 
research institutes and private industry in the TB vaccine field. 
A realistic strategy for TB vaccine development includes 
support for both upstream research and downstream clinical 
trials. It is imperative that a robust, healthy pipeline of TB 
vaccine concepts and candidates be maintained if the field is to 
move forward. The stage gating initiative, designed to encour-
age optimal management of the global TB vaccine portfolio, 
represents an important initiative in furthering this goal.
g. Proposed stage gate criteria for TB vaccines
Projects stages, stage gates, and stage-gate criteria are a suite of 
tools that allow effective management of large R&D programs 
by sponsors and funders. An R&D program can be divided into 
segments referred to as stages, wherein multiple mostly related 
activities are conducted in parallel. Stage gates are defined as 
check points that separate the stages and the stage-gate crite-
ria constitute a set of objective, pre-defined data targets upon 
which continuation of the project into the next stage is decided. 
A stage-gating tool has been in use by TBVI and AERAS since 
2010137.
The BMGF is now funding a new joint TBVI-Aeras effort to 
revise the general TB vaccine stage-gate criteria that will aid 
vaccine researchers and developers as well as develop more 
specific stage- gating criteria based on vaccine target populations 
and/or vaccine indications.
The stage-gate criteria will be revisited biannually to ensure that 
the latest knowledge and developments relevant to the develop-
ment of TB vaccines are included. The development process 
will include consultation with stakeholders participating in 
TB vaccine development.
Four different indications for TB vaccines will be addressed 
under the stage-gate criteria: 1) prevention of TB disease in 
pediatric, adolescent and adult/elderly populations; 2) BCG 
replacement in infants; 3) prevention of TB disease recurrence; 
and 4) immunotherapy of active TB disease. Stage gating criteria 
for these indications may differ in pre-clinical immunogenicity, 
efficacy and safety requirements; in clinical development 
strategy, including safety, immunogenicity and efficacy targets, 
and target populations; and in regulatory and marketing targets. 
Commonalities between indications will be found in process 
and manufacturing criteria, and well as in the overall precut 
characteristics. These differences and commonalities ultimately 
will be reflected in the stage gating criteria. Efforts towards 
the finalization of the stage gating document are underway.
7. Conclusions
As the TB vaccine development field moves forward, it will 
be important to educate potential funders as to the barriers 
faced in conducting clinical trials of TB vaccines and to clearly 
frame the specific goals of these trials. The WHO holds an 
important responsibility for bringing researchers and funders 
together in support of needed efforts.
The WHO has provided excellent leadership through its intro-
duction of preferred product criteria (PPC) for TB vaccine 
development5. Importantly, the criteria appear to be flexible 
enough to keep open many directions in TB vaccine research 
and avoiding the trap of focusing on the wrong strategic 
priorities. While the WHO is presenting different PPCs for 
TB vaccines targeting infants and adolescents/adults, respec-
tively, it will be important to model the effect of using adult and 
infant vaccines together to end the TB epidemic.
This is a critically important juncture for TB vaccine develop-
ment. Results from the recently concluded BCG revaccination 
study in South African adolescents at high risk of acquiring 
Mtb infection have reemphasized the potential promise of 
looking at this old vaccine in new ways12. M72/AS01E candidate 
vaccine results, published after the meeting reported here, 
constitute a major encouragement for the field, and argue in 
favor of strengthening global health stakeholder engagement and 
funding for further TB vaccine R&D efforts138. Ongoing, robust 
support for TB vaccine development will be critical to ensuring 
that a TB vaccine is available to help end the global scourge of 
tuberculosis.
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